Table 1.23  
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity  
Both Sexes

<table>
<thead>
<tr>
<th>All Races</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>White</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>Black</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate(^f)</td>
<td>66.5</td>
<td>-1.9*</td>
<td></td>
<td>Prostate(^f)</td>
<td>67.6</td>
<td>-1.3*</td>
<td></td>
<td>Prostate(^f)</td>
</tr>
<tr>
<td>Breast</td>
<td>67.9</td>
<td>-1.2*</td>
<td></td>
<td>Breast</td>
<td>67.9</td>
<td>-2.2*</td>
<td></td>
<td>Breast</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>62.5</td>
<td>-1.5*</td>
<td></td>
<td>Lung and Bronchus</td>
<td>63.4</td>
<td>-1.5*</td>
<td></td>
<td>Lung and Bronchus</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>47.9</td>
<td>-2.6*</td>
<td></td>
<td>Colon and Rectum</td>
<td>47.4</td>
<td>-2.8*</td>
<td></td>
<td>Colon and Rectum</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>21.1</td>
<td>-0.4</td>
<td></td>
<td>Urinary Bladder</td>
<td>22.8</td>
<td>-0.4*</td>
<td></td>
<td>Urinary Bladder</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>20.1</td>
<td>1.6*</td>
<td></td>
<td>Melanoma of the Skin</td>
<td>23.5</td>
<td>2.0*</td>
<td></td>
<td>Melanoma of the Skin</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>19.6</td>
<td>0.1</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>20.5</td>
<td>0.2</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>14.1</td>
<td>2.4*</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>14.5</td>
<td>2.4*</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS(^f)</td>
<td>12.6</td>
<td>-0.7*</td>
<td></td>
<td>Corpus and Uterus, NOS(^f)</td>
<td>13.0</td>
<td>-1.0*</td>
<td></td>
<td>Corpus and Uterus, NOS(^f)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>12.3</td>
<td>-0.8*</td>
<td></td>
<td>Leukemia</td>
<td>12.9</td>
<td>-0.7*</td>
<td></td>
<td>Leukemia</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11.7</td>
<td>0.7*</td>
<td></td>
<td>Pancreas</td>
<td>11.6</td>
<td>0.8*</td>
<td></td>
<td>Pancreas</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>10.4</td>
<td>-1.1</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
<td>10.7</td>
<td>6.3*</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
</tr>
<tr>
<td>Stomach</td>
<td>7.8</td>
<td>-1.7*</td>
<td></td>
<td>Stomach</td>
<td>7.3</td>
<td>-2.0*</td>
<td></td>
<td>Stomach</td>
</tr>
<tr>
<td>Ovary(^f)</td>
<td>7.0</td>
<td>-1.8*</td>
<td></td>
<td>Ovary(^f)</td>
<td>7.3</td>
<td>-2.0*</td>
<td></td>
<td>Ovary(^f)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asian/Pacific Islander</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>American Indian/Alaska Native(^d)</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>Hispanic(^e)</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>49.1</td>
<td>-0.4</td>
<td></td>
<td>Breast</td>
<td>45.3</td>
<td>0.8</td>
<td></td>
<td>Breast</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>43.9</td>
<td>-2.1*</td>
<td></td>
<td>Colon and Rectum</td>
<td>42.1</td>
<td>-1.7</td>
<td></td>
<td>Colon and Rectum</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>38.7</td>
<td>-1.1*</td>
<td></td>
<td>Lung and Bronchus</td>
<td>34.0</td>
<td>-0.7*</td>
<td></td>
<td>Lung and Bronchus</td>
</tr>
<tr>
<td>Liver &amp; IBD(^g)</td>
<td>14.4</td>
<td>0.6</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>17.4</td>
<td>3.8*</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
</tr>
<tr>
<td>Stomach</td>
<td>13.2</td>
<td>-3.1*</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>11.4</td>
<td>-0.4</td>
<td></td>
<td>Stomach</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>12.9</td>
<td>-1.0</td>
<td></td>
<td>Stomach</td>
<td>10.9</td>
<td>-3.7</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Thyroid</td>
<td>10.1</td>
<td>4.4*</td>
<td></td>
<td>Stomach</td>
<td>10.6</td>
<td>0.8</td>
<td></td>
<td>Thyroid</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS(^f)</td>
<td>9.4</td>
<td>1.0</td>
<td></td>
<td>Pancreas</td>
<td>10.6</td>
<td>1.1</td>
<td></td>
<td>Pancreas</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>9.1</td>
<td>0.6</td>
<td></td>
<td>Corpus and Uterus, NOS(^f)</td>
<td>9.0</td>
<td>0.4</td>
<td></td>
<td>Corpus and Uterus, NOS(^f)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.1</td>
<td>-0.2</td>
<td></td>
<td>Urinary Bladder</td>
<td>7.7</td>
<td>-</td>
<td></td>
<td>Urinary Bladder</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>7.6</td>
<td>-1.3</td>
<td></td>
<td>Urinary Bladder</td>
<td>7.3</td>
<td>-5.2</td>
<td></td>
<td>Urinary Bladder</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>7.3</td>
<td>3.6*</td>
<td></td>
<td>Pancreas</td>
<td>6.5</td>
<td>-2.3</td>
<td></td>
<td>Pancreas</td>
</tr>
<tr>
<td>Leukemia</td>
<td>7.2</td>
<td>-1.5*</td>
<td></td>
<td>Ovary(^f)</td>
<td>5.9</td>
<td>-1.3</td>
<td></td>
<td>Ovary(^f)</td>
</tr>
<tr>
<td>Ovary(^f)</td>
<td>5.3</td>
<td>-0.2</td>
<td></td>
<td>Thyroid</td>
<td>5.8</td>
<td>-1.6</td>
<td></td>
<td>Ovary(^f)</td>
</tr>
</tbody>
</table>

\(^a\) Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.
\(^b\) Rates are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).
\(^c\) The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
\(^d\) Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).
\(^e\) American Indian/Alaska Native are based on the CHSDA/Contract Health Service Delivery Area) counties.
\(^f\) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
\(^g\) Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
\(^h\) Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
### Table 1.24
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

#### Males

<table>
<thead>
<tr>
<th>All Races</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
<th>White</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Black</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>538.9</td>
<td>-1.2&lt;sup&gt;*&lt;/sup&gt;</td>
<td>All Sites</td>
<td>541.5</td>
<td>-1.1&lt;sup&gt;*&lt;/sup&gt;</td>
<td>All Sites</td>
<td>624.0</td>
<td>-2.4&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prostate</td>
<td>156.9</td>
<td>-1.7&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Prostate</td>
<td>150.4</td>
<td>-1.8&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Prostate</td>
<td>234.6</td>
<td>-3.1&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>76.2</td>
<td>-2.4&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Lung and Bronchus</td>
<td>76.3</td>
<td>-2.4&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Lung and Bronchus</td>
<td>101.2</td>
<td>-3.4&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>55.8</td>
<td>-3.2&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Colon and Rectum</td>
<td>55.4</td>
<td>-3.2&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Colon and Rectum</td>
<td>68.1</td>
<td>-2.3&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>37.2</td>
<td>-0.5&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Urinary Bladder</td>
<td>40.4</td>
<td>-0.5&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Urinary Bladder</td>
<td>21.8</td>
<td>1.9</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>25.6</td>
<td>1.7&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Melanoma of the Skin</td>
<td>29.7</td>
<td>2.0&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Melanoma of the Skin</td>
<td>20.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>23.6</td>
<td>0.1</td>
<td>Non-Hodgkin Lymphoma</td>
<td>24.6</td>
<td>0.2</td>
<td>Non-Hodgkin Lymphoma</td>
<td>17.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>19.2</td>
<td>2.0&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Kidney and Renal Pelvis</td>
<td>19.7</td>
<td>2.0&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Kidney and Renal Pelvis</td>
<td>16.7</td>
<td>-2.1&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Leukemia</td>
<td>15.8</td>
<td>-1.2&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Leukemia</td>
<td>16.6</td>
<td>-1.0&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Leukemia</td>
<td>16.7</td>
<td>-0.7&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>15.4</td>
<td>-1.3&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Oral Cavity and Pharynx</td>
<td>15.7</td>
<td>-0.9&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Oral Cavity and Pharynx</td>
<td>16.1</td>
<td>-4.1&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pancreas</td>
<td>13.3</td>
<td>0.1</td>
<td>Pancreas</td>
<td>13.7</td>
<td>0.1</td>
<td>Pancreas</td>
<td>14.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>10.9</td>
<td>-1.9&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Stomach</td>
<td>11.2</td>
<td>-1.8&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Stomach</td>
<td>14.0</td>
<td>3.6&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>10.7</td>
<td>2.6&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>10.6</td>
<td>2.6&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>11.2</td>
<td>-0.7&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7.8</td>
<td>-0.9</td>
<td>Esophagus</td>
<td>7.4</td>
<td>-0.5</td>
<td>Esophagus</td>
<td>8.9</td>
<td>-4.5&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>7.6</td>
<td>-0.7&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>8.0</td>
<td>-0.2</td>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>4.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>7.1</td>
<td>-0.4</td>
<td>Myeloma</td>
<td>6.7</td>
<td>-0.4</td>
<td>Myeloma</td>
<td>6.7</td>
<td>-0.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asian/Pacific Islander</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
<th>American Indian/Alaska Native&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Hispanic&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt;</th>
<th>APC&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>346.5</td>
<td>-1.1&lt;sup&gt;*&lt;/sup&gt;</td>
<td>All Sites</td>
<td>335.8</td>
<td>-1.5</td>
<td>All Sites</td>
<td>394.8</td>
<td>-1.8&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prostate</td>
<td>90.0</td>
<td>-1.1</td>
<td>Prostate</td>
<td>77.7</td>
<td>-0.7</td>
<td>Prostate</td>
<td>125.8</td>
<td>-2.7&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>52.9</td>
<td>-1.6&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Lung and Bronchus</td>
<td>52.7</td>
<td>-1.2</td>
<td>Lung and Bronchus</td>
<td>44.5</td>
<td>-2.3&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>45.5</td>
<td>-2.5&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Colon and Rectum</td>
<td>43.4</td>
<td>-1.9</td>
<td>Colon and Rectum</td>
<td>41.4</td>
<td>-2.8&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>21.1</td>
<td>0.7</td>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>21.4</td>
<td>1.6</td>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>19.2</td>
<td>-1.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>17.5</td>
<td>-2.6&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Stomach</td>
<td>15.5</td>
<td>-2.7</td>
<td>Stomach</td>
<td>17.5</td>
<td>1.5&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>16.0</td>
<td>0.3</td>
<td>Urinary Bladder</td>
<td>14.6</td>
<td>-</td>
<td>Urinary Bladder</td>
<td>15.6</td>
<td>2.2&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>15.7</td>
<td>-1.0</td>
<td>Non-Hodgkin Lymphoma</td>
<td>12.5</td>
<td>-</td>
<td>Non-Hodgkin Lymphoma</td>
<td>14.8</td>
<td>-2.7&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>10.5</td>
<td>-1.5</td>
<td>Oral Cavity and Pharynx</td>
<td>10.6</td>
<td>-</td>
<td>Oral Cavity and Pharynx</td>
<td>11.2</td>
<td>-0.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.2</td>
<td>1.3</td>
<td>Pancreas</td>
<td>9.6</td>
<td>-</td>
<td>Pancreas</td>
<td>10.9</td>
<td>1.1</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>10.2</td>
<td>3.1&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Kidney and Renal Pelvis</td>
<td>7.2</td>
<td>-</td>
<td>Kidney and Renal Pelvis</td>
<td>8.7</td>
<td>-2.2</td>
</tr>
<tr>
<td>Leukemia</td>
<td>8.8</td>
<td>-2.3&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Leukemia</td>
<td>5.2</td>
<td>-</td>
<td>Leukemia</td>
<td>6.3</td>
<td>-0.5</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.4</td>
<td>2.9</td>
<td>Thyroid</td>
<td>4.1</td>
<td>2.9</td>
<td>Thyroid</td>
<td>5.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.1</td>
<td>-2.8&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Esophagus</td>
<td>4.7</td>
<td>-</td>
<td>Esophagus</td>
<td>5.1</td>
<td>-2.7</td>
</tr>
<tr>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>4.0</td>
<td>-1.9</td>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>4.1</td>
<td>-</td>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>4.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>4.0</td>
<td>-1.0</td>
<td>Myeloma</td>
<td>3.8</td>
<td>-</td>
<td>Myeloma</td>
<td>4.6</td>
<td>-3.0&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

---

* Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.

b Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Rates are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

c The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

f Incidence data for Hispanics are based on NHIS and exclude cases from the Alaska Native Registry.

g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

h The APC is significantly different from zero (p<.05).

i Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
## Table 1.25
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

<table>
<thead>
<tr>
<th>Females</th>
<th>Rate(^b) 2003-2007</th>
<th>Rate(^b) 1998-2007</th>
<th>APC(^c)</th>
<th>Rate(^b) 2003-2007</th>
<th>Rate(^b) 1998-2007</th>
<th>APC(^c)</th>
<th>Rate(^b) 2003-2007</th>
<th>Rate(^b) 1998-2007</th>
<th>APC(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Races</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>408.0</td>
<td>-0.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>122.9</td>
<td>-1.7*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>52.4</td>
<td>-0.5*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>41.7</td>
<td>-2.4*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>23.5</td>
<td>-0.5*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>16.5</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>16.2</td>
<td>1.6*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>15.2</td>
<td>6.5*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary(^d)</td>
<td>12.9</td>
<td>-1.6*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>10.5</td>
<td>0.9*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>9.9</td>
<td>2.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>9.2</td>
<td>-0.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>8.1</td>
<td>-3.2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>6.1</td>
<td>-1.1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>5.5</td>
<td>-1.7*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asian/Pacific Islander</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>288.9</td>
<td>-0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>90.0</td>
<td>-0.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>34.2</td>
<td>-1.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>17.3</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>15.2</td>
<td>4.9*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>10.8</td>
<td>-0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>10.0</td>
<td>-3.4*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary(^d)</td>
<td>9.8</td>
<td>-0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD(^f)</td>
<td>8.3</td>
<td>0.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>8.3</td>
<td>-0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>7.5</td>
<td>-3.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.0</td>
<td>-0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.3</td>
<td>-1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>5.1</td>
<td>4.2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.0</td>
<td>-1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>American Indian/Alaska Native</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>306.3</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>76.4</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>40.4</td>
<td>-1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>16.1</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>14.1</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary(^g)</td>
<td>10.9</td>
<td>-1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.1</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>2.1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>7.3</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>7.3</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD(^f)</td>
<td>6.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.0</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.2</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.7</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hispanic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>309.2</td>
<td>-0.9*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>86.0</td>
<td>1.2*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>31.6</td>
<td>-1.1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>25.4</td>
<td>-1.6*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>17.6</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>14.5</td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>13.3</td>
<td>5.8*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>12.0</td>
<td>-4.9*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary(^d)</td>
<td>11.0</td>
<td>-5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.1</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>10.0</td>
<td>2.1*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>9.1</td>
<td>-1.4*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>8.0</td>
<td>-0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD(^f)</td>
<td>6.0</td>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.1</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.7</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>4.7</td>
<td>-1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.**
- **Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJMD/LA, Kentucky, Louisiana and New Jersey).**
- **The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).**
- **Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.**
- **Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indian/Alaska Natives.**
- **The APC is significantly different from zero (p<.05).**
- **Statistical not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.**

\(^{a}\) Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.
\(^{b}\) Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJMD/LA, Kentucky, Louisiana and New Jersey).
\(^{c}\) The APC is the Annual Percent Change over the time interval. Incidence data used in calculating the trends are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
\(^{d}\) Rates are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
\(^{e}\) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indian/Alaska Natives.
\(^{f}\) Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
\(^{g}\) Rates for American Indian/Alaska Native are based on the CHSDDA (Contract Health Service Delivery Area) counties.
\(^{h}\) White excludes cases or histologies 8442, 8451, 8462, 8472, and 8473.
Table 1.26
Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites\(^a\) by Race/Ethnicity

<table>
<thead>
<tr>
<th>All Races</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>White</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
<th>Black</th>
<th>Rate(^b)</th>
<th>APC(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>183.8</td>
<td>-1.4(*)</td>
<td>All Sites</td>
<td>182.4</td>
<td>-1.3(*)</td>
<td>All Sites</td>
<td>224.2</td>
<td>-2.0(*)</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>52.5</td>
<td>-1.2(*)</td>
<td>Lung and Bronchus</td>
<td>52.9</td>
<td>-1.0(*)</td>
<td>Lung and Bronchus</td>
<td>58.6</td>
<td>-1.8(*)</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.6</td>
<td>-2.9(*)</td>
<td>Colon and Rectum</td>
<td>17.1</td>
<td>-2.9(*)</td>
<td>Colon and Rectum</td>
<td>24.7</td>
<td>-2.3(*)</td>
</tr>
<tr>
<td>Breast</td>
<td>13.5</td>
<td>-2.3(*)</td>
<td>Breast</td>
<td>13.3</td>
<td>-2.3(*)</td>
<td>Breast</td>
<td>19.3</td>
<td>-3.8(*)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.7</td>
<td>0.3(*)</td>
<td>Pancreas</td>
<td>10.5</td>
<td>0.4(*)</td>
<td>Pancreas</td>
<td>19.2</td>
<td>-1.5(*)</td>
</tr>
<tr>
<td>Prostate(^f)</td>
<td>9.5</td>
<td>-3.2(*)</td>
<td>Prostate(^f)</td>
<td>8.8</td>
<td>-3.0(*)</td>
<td>Prostate(^f)</td>
<td>13.8</td>
<td>-0.4(*)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>7.2</td>
<td>-1.0(*)</td>
<td>Leukemia</td>
<td>7.4</td>
<td>-0.9(*)</td>
<td>Leukemia</td>
<td>7.3</td>
<td>-3.7(*)</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>6.9</td>
<td>-3.2(*)</td>
<td>Non-Hodgkin Lymphoma</td>
<td>7.2</td>
<td>-3.2(*)</td>
<td>Non-Hodgkin Lymphoma</td>
<td>7.0</td>
<td>2.0(*)</td>
</tr>
<tr>
<td>Liver &amp; IBD(^g)</td>
<td>5.2</td>
<td>2.1(*)</td>
<td>Liver &amp; IBD(^g)</td>
<td>5.0</td>
<td>0.7(*)</td>
<td>Liver &amp; IBD(^g)</td>
<td>6.7</td>
<td>-2.0(*)</td>
</tr>
<tr>
<td>Ovary(^f)</td>
<td>4.8</td>
<td>-0.8(*)</td>
<td>Ovary(^f)</td>
<td>4.8</td>
<td>2.2(*)</td>
<td>Ovary(^f)</td>
<td>6.3</td>
<td>-1.4(*)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.4</td>
<td>-0.1(*)</td>
<td>Esophagus</td>
<td>4.6</td>
<td>-1.1(*)</td>
<td>Esophagus</td>
<td>5.1</td>
<td>-4.5(*)</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.3</td>
<td>0.0(*)</td>
<td>Urinary Bladder</td>
<td>4.5</td>
<td>0.2(*)</td>
<td>Urinary Bladder</td>
<td>4.8</td>
<td>-2.6(*)</td>
</tr>
<tr>
<td>Brain and ONS(^g)</td>
<td>4.3</td>
<td>-1.2(*)</td>
<td>Brain and ONS(^g)</td>
<td>4.4</td>
<td>0.7(*)</td>
<td>Brain and ONS(^g)</td>
<td>4.3</td>
<td>0.6(*)</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>4.1</td>
<td>-0.6(*)</td>
<td>Kidney and Renal Pelvis</td>
<td>4.2</td>
<td>-0.5(*)</td>
<td>Kidney and Renal Pelvis</td>
<td>4.0</td>
<td>-0.4(*)</td>
</tr>
<tr>
<td>Stomach</td>
<td>3.8</td>
<td>-3.2(*)</td>
<td>Stomach</td>
<td>3.3</td>
<td>-3.3(*)</td>
<td>Stomach</td>
<td>3.7</td>
<td>-0.6(*)</td>
</tr>
<tr>
<td>Myeloma</td>
<td>3.6</td>
<td>-1.3(*)</td>
<td>Myeloma</td>
<td>3.3</td>
<td>-1.2(*)</td>
<td>Myeloma</td>
<td>3.7</td>
<td>-0.6(*)</td>
</tr>
<tr>
<td>American Indian/Alaska Native(^d)</td>
<td>Rate(^b)</td>
<td>APC(^c)</td>
<td>All Sites</td>
<td>156.7</td>
<td>-0.5(*)</td>
<td>All Sites</td>
<td>122.1</td>
<td>-1.8(*)</td>
</tr>
<tr>
<td>All Sites</td>
<td>110.8</td>
<td>-1.6(*)</td>
<td>All Sites</td>
<td>155.7</td>
<td>-0.5(*)</td>
<td>All Sites</td>
<td>122.1</td>
<td>-1.8(*)</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>26.2</td>
<td>-1.3(*)</td>
<td>Lung and Bronchus</td>
<td>39.7</td>
<td>-0.5(*)</td>
<td>Lung and Bronchus</td>
<td>22.1</td>
<td>-2.1(*)</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>11.3</td>
<td>-2.3(*)</td>
<td>Colon and Rectum</td>
<td>15.5</td>
<td>-2.0(*)</td>
<td>Colon and Rectum</td>
<td>12.7</td>
<td>-2.0(*)</td>
</tr>
<tr>
<td>Liver &amp; IBD(^g)</td>
<td>10.1</td>
<td>-1.1(*)</td>
<td>Liver &amp; IBD(^g)</td>
<td>8.3</td>
<td>-2.2(*)</td>
<td>Liver &amp; IBD(^g)</td>
<td>8.4</td>
<td>-2.2(*)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>7.4</td>
<td>0.0(*)</td>
<td>Pancreas</td>
<td>8.6</td>
<td>2.0(*)</td>
<td>Pancreas</td>
<td>8.3</td>
<td>-0.1(*)</td>
</tr>
<tr>
<td>Stomach</td>
<td>7.2</td>
<td>-3.7(*)</td>
<td>Stomach</td>
<td>6.3</td>
<td>-3.5(*)</td>
<td>Stomach</td>
<td>6.0</td>
<td>-3.3(*)</td>
</tr>
<tr>
<td>Breast</td>
<td>6.8</td>
<td>-0.9(*)</td>
<td>Breast</td>
<td>8.0</td>
<td>-1.1(*)</td>
<td>Breast (^f)</td>
<td>7.5</td>
<td>-3.1(*)</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>4.4</td>
<td>-3.2(*)</td>
<td>Non-Hodgkin Lymphoma</td>
<td>4.9</td>
<td>-2.1(*)</td>
<td>Non-Hodgkin Lymphoma</td>
<td>5.3</td>
<td>-3.1(*)</td>
</tr>
<tr>
<td>Prostate(^f)</td>
<td>4.3</td>
<td>-3.4(*)</td>
<td>Prostate(^f)</td>
<td>4.9</td>
<td>-2.1(*)</td>
<td>Prostate(^f)</td>
<td>4.8</td>
<td>-1.6(*)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.8</td>
<td>-1.6(*)</td>
<td>Leukemia</td>
<td>4.8</td>
<td>1.4(*)</td>
<td>Leukemia</td>
<td>3.6</td>
<td>-0.3(*)</td>
</tr>
<tr>
<td>Ovary(^f)</td>
<td>2.7</td>
<td>0.8(*)</td>
<td>Ovary(^f)</td>
<td>3.8</td>
<td>0.2(*)</td>
<td>Ovary(^f)</td>
<td>3.3</td>
<td>-0.5(*)</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>2.1</td>
<td>-2.2(*)</td>
<td>Oral Cavity and Pharynx</td>
<td>3.8</td>
<td>0.2(*)</td>
<td>Oral Cavity and Pharynx</td>
<td>2.9</td>
<td>-1.2(*)</td>
</tr>
<tr>
<td>Brain and ONS(^g)</td>
<td>1.9</td>
<td>-0.2(*)</td>
<td>Brain and ONS(^g)</td>
<td>3.8</td>
<td>0.6(*)</td>
<td>Brain and ONS(^g)</td>
<td>2.8</td>
<td>-0.9(*)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>1.9</td>
<td>-1.7(*)</td>
<td>Esophagus</td>
<td>3.5</td>
<td>-2.6(*)</td>
<td>Esophagus</td>
<td>2.2</td>
<td>-2.0(*)</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>1.8</td>
<td>0.1(*)</td>
<td>Kidney and Renal Pelvis</td>
<td>2.4</td>
<td>-0.4(*)</td>
<td>Kidney and Renal Pelvis</td>
<td>2.2</td>
<td>-2.0(*)</td>
</tr>
<tr>
<td>Myeloma</td>
<td>1.7</td>
<td>-1.0(*)</td>
<td>Myeloma</td>
<td>2.1</td>
<td>0.4(*)</td>
<td>Myeloma</td>
<td>2.1</td>
<td>0.4(*)</td>
</tr>
</tbody>
</table>

\(^a\) Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.
\(^b\) Mortality data used in calculating the rates are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
\(^c\) The APC is the Annual Percent Change over the time interval. Mortality data used in calculating the trends are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
\(^d\) Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
\(^e\) Hispanic is not mutually exclusive with whites, blacks, Asian/Pacific Islanders, and American Indian/Alaska Natives. The 2003-2007 Hispanic death rates do not include deaths from the District of Columbia, New Hampshire and North Dakota.
\(^f\) The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
\(^g\) IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
\(^h\) The APC is significantly different from zero (p<.05).
\(^i\) Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
### Table 1.27
Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt; 2003-2007</th>
<th>Rate&lt;sup&gt;c&lt;/sup&gt; 1998-2007</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt; 2003-2007</th>
<th>Rate&lt;sup&gt;c&lt;/sup&gt; 1998-2007</th>
<th>Rate&lt;sup&gt;b&lt;/sup&gt; 2003-2007</th>
<th>Rate&lt;sup&gt;c&lt;/sup&gt; 1998-2007</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Races</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>225.4</td>
<td>-1.8*</td>
<td>222.5</td>
<td>-1.7*</td>
<td>222.5</td>
<td>-1.7*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>68.8</td>
<td>-2.1*</td>
<td>68.3</td>
<td>-1.9*</td>
<td>68.3</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Prostate</td>
<td>24.7</td>
<td>-3.9*</td>
<td>22.8</td>
<td>-3.8*</td>
<td>22.8</td>
<td>-3.8*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>21.2</td>
<td>-3.1*</td>
<td>20.8</td>
<td>-3.1*</td>
<td>20.8</td>
<td>-3.1*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>12.3</td>
<td>0.2</td>
<td>12.2</td>
<td>0.4</td>
<td>12.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>9.7</td>
<td>-0.9*</td>
<td>10.0</td>
<td>-0.8*</td>
<td>10.0</td>
<td>-0.8*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>8.7</td>
<td>-3.0*</td>
<td>9.1</td>
<td>-3.0*</td>
<td>9.1</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7.8</td>
<td>0.2</td>
<td>7.9</td>
<td>0.9</td>
<td>7.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>7.7</td>
<td>2.2*</td>
<td>7.0</td>
<td>2.2*</td>
<td>7.0</td>
<td>2.2*</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>7.5</td>
<td>-0.1</td>
<td>6.0</td>
<td>-0.7*</td>
<td>6.0</td>
<td>-0.7*</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>5.9</td>
<td>-0.7*</td>
<td>5.6</td>
<td>-1.1*</td>
<td>5.6</td>
<td>-1.1*</td>
</tr>
<tr>
<td>Stomach</td>
<td>5.3</td>
<td>-3.5*</td>
<td>5.6</td>
<td>-1.1*</td>
<td>5.6</td>
<td>-1.1*</td>
</tr>
<tr>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>5.2</td>
<td>-1.3*</td>
<td>4.6</td>
<td>-3.7*</td>
<td>4.6</td>
<td>-3.7*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>4.4</td>
<td>-1.0*</td>
<td>4.5</td>
<td>0.5</td>
<td>4.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>3.9</td>
<td>-1.5*</td>
<td>3.7</td>
<td>-1.1*</td>
<td>3.7</td>
<td>-1.1*</td>
</tr>
<tr>
<td><strong>Asian/Pacific Islander</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>134.2</td>
<td>-2.0*</td>
<td>183.7</td>
<td>-1.0</td>
<td>183.7</td>
<td>-1.0</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>36.7</td>
<td>-1.7*</td>
<td>48.1</td>
<td>-2.2*</td>
<td>48.1</td>
<td>-2.2*</td>
</tr>
<tr>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>14.7</td>
<td>-1.1*</td>
<td>20.0</td>
<td>-1.6</td>
<td>20.0</td>
<td>-1.6</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>13.2</td>
<td>-3.1*</td>
<td>19.2</td>
<td>-1.8</td>
<td>19.2</td>
<td>-1.8</td>
</tr>
<tr>
<td>Prostate</td>
<td>10.6</td>
<td>-3.1*</td>
<td>10.1</td>
<td>2.2</td>
<td>10.1</td>
<td>2.2</td>
</tr>
<tr>
<td>Stomach</td>
<td>9.4</td>
<td>-3.6*</td>
<td>9.9</td>
<td>3.5</td>
<td>9.9</td>
<td>3.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>8.2</td>
<td>0.0</td>
<td>9.2</td>
<td>1.7</td>
<td>9.2</td>
<td>1.7</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.5</td>
<td>-2.8*</td>
<td>8.8</td>
<td>0.7</td>
<td>8.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Leukemia</td>
<td>4.9</td>
<td>-1.0</td>
<td>6.4</td>
<td>0.0</td>
<td>6.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Esophagus</td>
<td>3.2</td>
<td>-2.0</td>
<td>5.8</td>
<td>0.1</td>
<td>5.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>3.1</td>
<td>-2.8*</td>
<td>5.3</td>
<td>3.7</td>
<td>5.3</td>
<td>3.7</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.6</td>
<td>0.2</td>
<td>4.2</td>
<td>-0.6</td>
<td>4.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>2.6</td>
<td>1.0*</td>
<td>3.5</td>
<td>-3.2</td>
<td>3.5</td>
<td>-3.2</td>
</tr>
<tr>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>2.3</td>
<td>-1.2</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.0</td>
<td>-0.1</td>
<td>2.7</td>
<td>3.1</td>
<td>2.7</td>
<td>3.1</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.0</td>
<td>-0.6</td>
<td>1.9</td>
<td>-0.6</td>
<td>1.9</td>
<td>-0.6</td>
</tr>
<tr>
<td><strong>American Indian/Alaska Native</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>183.7</td>
<td>-1.0</td>
<td>183.7</td>
<td>-1.0</td>
<td>183.7</td>
<td>-1.0</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>48.1</td>
<td>-2.2*</td>
<td>48.1</td>
<td>-2.2*</td>
<td>48.1</td>
<td>-2.2*</td>
</tr>
<tr>
<td>Prostate</td>
<td>20.0</td>
<td>-1.6</td>
<td>20.0</td>
<td>-1.6</td>
<td>20.0</td>
<td>-1.6</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>19.2</td>
<td>-1.8</td>
<td>19.2</td>
<td>-1.8</td>
<td>19.2</td>
<td>-1.8</td>
</tr>
<tr>
<td>Liver &amp; IBD&lt;sup&gt;f&lt;/sup&gt;</td>
<td>10.9</td>
<td>3.7*</td>
<td>10.9</td>
<td>3.7*</td>
<td>10.9</td>
<td>3.7*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.9</td>
<td>3.5</td>
<td>9.9</td>
<td>3.5</td>
<td>9.9</td>
<td>3.5</td>
</tr>
<tr>
<td>Stomach</td>
<td>9.2</td>
<td>1.7</td>
<td>9.2</td>
<td>1.7</td>
<td>9.2</td>
<td>1.7</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>8.8</td>
<td>-0.7</td>
<td>8.8</td>
<td>-0.7</td>
<td>8.8</td>
<td>-0.7</td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.4</td>
<td>0.0</td>
<td>6.4</td>
<td>0.0</td>
<td>6.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Esophagus</td>
<td>5.8</td>
<td>0.1</td>
<td>5.8</td>
<td>0.1</td>
<td>5.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.3</td>
<td>-3.7</td>
<td>5.3</td>
<td>-3.7</td>
<td>5.3</td>
<td>-3.7</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>4.2</td>
<td>-0.6</td>
<td>4.2</td>
<td>-0.6</td>
<td>4.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>3.5</td>
<td>-3.2</td>
<td>3.5</td>
<td>-3.2</td>
<td>3.5</td>
<td>-3.2</td>
</tr>
<tr>
<td>Brain and ONS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.7</td>
<td>3.1</td>
<td>2.7</td>
<td>3.1</td>
<td>2.7</td>
<td>3.1</td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.9</td>
<td>-0.6</td>
<td>1.9</td>
<td>-0.6</td>
<td>1.9</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

* Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.

b Mortality data used in calculating the rates are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

A The APC is the Annual Percent Change over the time interval. Mortality data used in calculating the trends are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).


The APC is significantly different from zero (p<.05).

f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

The APC is significantly different from zero (p<.05).

Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
### Table 1.28

Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites a by Race/Ethnicity

#### Females

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>155.4</td>
<td>-1.2*</td>
<td>Lung and Bronchus</td>
<td>155.0</td>
<td>-1.1*</td>
<td>Lung and Bronchus</td>
<td>180.6</td>
<td>-1.4*</td>
<td>Lung and Bronchus</td>
<td>39.6</td>
<td>-0.3</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>40.6</td>
<td>-0.2*</td>
<td>Breast</td>
<td>41.6</td>
<td>-0.1</td>
<td>Breast</td>
<td>32.4</td>
<td>-1.4*</td>
<td>Breast</td>
<td>21.9</td>
<td>-2.7</td>
</tr>
<tr>
<td>Breast</td>
<td>24.0</td>
<td>-2.0*</td>
<td>Colon and Rectum</td>
<td>23.4</td>
<td>-2.0*</td>
<td>Colon and Rectum</td>
<td>21.4</td>
<td>-2.7*</td>
<td>Colon and Rectum</td>
<td>21.4</td>
<td>-2.7</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>14.9</td>
<td>-2.9*</td>
<td>Pancreas</td>
<td>19.4</td>
<td>-2.9*</td>
<td>Pancreas</td>
<td>12.4</td>
<td>-0.2</td>
<td>Pancreas</td>
<td>7.2</td>
<td>0.8*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.4</td>
<td>0.3*</td>
<td>Ovary</td>
<td>9.1</td>
<td>0.4*</td>
<td>Ovary</td>
<td>7.2</td>
<td>-0.9</td>
<td>Ovary</td>
<td>7.2</td>
<td>-0.9</td>
</tr>
<tr>
<td>Ovary</td>
<td>8.6</td>
<td>-0.6*</td>
<td>Non-Hodgkin Lymphoma</td>
<td>8.9</td>
<td>-0.5</td>
<td>Non-Hodgkin Lymphoma</td>
<td>5.7</td>
<td>-3.5*</td>
<td>Non-Hodgkin Lymphoma</td>
<td>7.2</td>
<td>-0.9</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.5</td>
<td>-3.5*</td>
<td>Leukemia</td>
<td>5.6</td>
<td>-1.3*</td>
<td>Leukemia</td>
<td>5.8</td>
<td>-2.3*</td>
<td>Leukemia</td>
<td>5.8</td>
<td>-2.3*</td>
</tr>
<tr>
<td>Leukemia</td>
<td>5.4</td>
<td>-1.4*</td>
<td>Corpus and Uterus, NOS</td>
<td>3.9</td>
<td>0.1</td>
<td>Corpus and Uterus, NOS</td>
<td>5.0</td>
<td>-4.0*</td>
<td>Corpus and Uterus, NOS</td>
<td>7.2</td>
<td>0.8*</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>4.1</td>
<td>0.2</td>
<td>Brain and ONS f</td>
<td>3.8</td>
<td>-1.1*</td>
<td>Brain and ONS f</td>
<td>5.0</td>
<td>-1.5*</td>
<td>Brain and ONS f</td>
<td>4.4</td>
<td>-3.5*</td>
</tr>
<tr>
<td>Brain and ONS f</td>
<td>3.5</td>
<td>-1.2*</td>
<td>Liver &amp; IBD f</td>
<td>3.0</td>
<td>1.6*</td>
<td>Liver &amp; IBD f</td>
<td>3.9</td>
<td>0.4</td>
<td>Liver &amp; IBD f</td>
<td>3.9</td>
<td>0.4</td>
</tr>
<tr>
<td>Liver &amp; IBD f</td>
<td>3.2</td>
<td>1.4*</td>
<td>Myeloma</td>
<td>2.7</td>
<td>-0.5*</td>
<td>Myeloma</td>
<td>2.7</td>
<td>-1.6*</td>
<td>Myeloma</td>
<td>2.7</td>
<td>-1.1</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.9</td>
<td>-1.8*</td>
<td>Stomach</td>
<td>2.4</td>
<td>-3.1*</td>
<td>Stomach</td>
<td>2.7</td>
<td>-1.1</td>
<td>Stomach</td>
<td>2.7</td>
<td>-0.2</td>
</tr>
<tr>
<td>Stomach</td>
<td>2.7</td>
<td>-3.0*</td>
<td>Kidney and Renal Pelvis</td>
<td>2.2</td>
<td>-0.4</td>
<td>Kidney and Renal Pelvis</td>
<td>2.7</td>
<td>-0.2</td>
<td>Kidney and Renal Pelvis</td>
<td>2.7</td>
<td>-0.2</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.7</td>
<td>-0.6*</td>
<td>Cervix Uteri</td>
<td>2.4</td>
<td>-2.4*</td>
<td>Cervix Uteri</td>
<td>2.2</td>
<td>-2.2*</td>
<td>Cervix Uteri</td>
<td>2.2</td>
<td>-2.2*</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>2.4</td>
<td>-2.4*</td>
<td>Urinary Bladder</td>
<td>2.2</td>
<td>0.4</td>
<td>Urinary Bladder</td>
<td>2.2</td>
<td>0.4</td>
<td>Urinary Bladder</td>
<td>2.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>2.2</td>
<td>-0.6*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Asian/Pacific Islander

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>94.1</td>
<td>-1.2*</td>
<td>Lung and Bronchus</td>
<td>138.0</td>
<td>-0.2</td>
<td>Lung and Bronchus</td>
<td>102.3</td>
<td>-1.3*</td>
<td>Lung and Bronchus</td>
<td>15.3</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>18.5</td>
<td>-0.6</td>
<td>Breast</td>
<td>33.3</td>
<td>1.2</td>
<td>Breast</td>
<td>14.4</td>
<td>0.4</td>
<td>Breast</td>
<td>14.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Breast</td>
<td>12.2</td>
<td>-1.0</td>
<td>Colon and Rectum</td>
<td>12.9</td>
<td>-2.3</td>
<td>Colon and Rectum</td>
<td>10.5</td>
<td>-1.5*</td>
<td>Colon and Rectum</td>
<td>10.5</td>
<td>-1.5*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>6.9</td>
<td>0.1</td>
<td>Pancreas</td>
<td>8.1</td>
<td>1.6</td>
<td>Pancreas</td>
<td>7.5</td>
<td>0.2</td>
<td>Pancreas</td>
<td>7.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.4</td>
<td>-1.2</td>
<td>Ovary</td>
<td>6.8</td>
<td>0.2</td>
<td>Ovary</td>
<td>6.0</td>
<td>-0.1</td>
<td>Ovary</td>
<td>6.0</td>
<td>-0.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>5.6</td>
<td>-3.5*</td>
<td>Liver &amp; IBD f</td>
<td>6.6</td>
<td>1.4</td>
<td>Liver &amp; IBD f</td>
<td>5.2</td>
<td>0.5</td>
<td>Liver &amp; IBD f</td>
<td>5.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Liver &amp; IBD f</td>
<td>4.9</td>
<td>0.6</td>
<td>Non-Hodgkin Lymphoma</td>
<td>4.6</td>
<td>-0.7</td>
<td>Non-Hodgkin Lymphoma</td>
<td>4.6</td>
<td>-3.0*</td>
<td>Non-Hodgkin Lymphoma</td>
<td>4.6</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.5</td>
<td>-3.4*</td>
<td>Stomach</td>
<td>4.2</td>
<td>-5.9*</td>
<td>Stomach</td>
<td>4.6</td>
<td>-3.0*</td>
<td>Stomach</td>
<td>4.6</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Stomach</td>
<td>2.9</td>
<td>-2.1*</td>
<td>Leukemia</td>
<td>3.9</td>
<td>-</td>
<td>Leukemia</td>
<td>3.9</td>
<td>-</td>
<td>Leukemia</td>
<td>3.9</td>
<td>-</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2.9</td>
<td>1.5</td>
<td>Kidney and Renal Pelvis</td>
<td>3.8</td>
<td>-2.5</td>
<td>Kidney and Renal Pelvis</td>
<td>3.1</td>
<td>-2.3*</td>
<td>Kidney and Renal Pelvis</td>
<td>3.1</td>
<td>-2.3*</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.1</td>
<td>-4.6*</td>
<td>Cervix Uteri</td>
<td>3.4</td>
<td>-2.4</td>
<td>Cervix Uteri</td>
<td>3.0</td>
<td>-0.9</td>
<td>Cervix Uteri</td>
<td>3.0</td>
<td>-0.9</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>1.6</td>
<td>1.2</td>
<td>Myeloma</td>
<td>3.0</td>
<td>-4.2</td>
<td>Myeloma</td>
<td>2.5</td>
<td>-1.0</td>
<td>Myeloma</td>
<td>2.5</td>
<td>-1.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td>1.4</td>
<td>-1.8</td>
<td>Corpus and Uterus, NOS</td>
<td>2.9</td>
<td></td>
<td>Corpus and Uterus, NOS</td>
<td>2.4</td>
<td>-0.7</td>
<td>Corpus and Uterus, NOS</td>
<td>2.4</td>
<td>-0.7</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>1.2</td>
<td>-0.9</td>
<td>Oral Cavity and Pharynx</td>
<td>2.4</td>
<td>-</td>
<td>Oral Cavity and Pharynx</td>
<td>2.4</td>
<td>-</td>
<td>Oral Cavity and Pharynx</td>
<td>2.4</td>
<td>-</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>1.2</td>
<td>-0.9</td>
<td>Kidney and Renal Pelvis</td>
<td>1.7</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>1.3</td>
<td>-0.7</td>
<td>Kidney and Renal Pelvis</td>
<td>1.3</td>
<td>-0.7</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>1.2</td>
<td>-0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Notes

a Top 15 cancer sites selected based on 2003-2007 age-adjusted rates for the race/ethnic group.

b Mortality data used in calculating the rates are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

c The APC is the Annual Percent Change over the time interval. Mortality data used in calculating the trends are analyzed from US mortality files provided by the National Center for Health Statistics, CDC. Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. The 2003-2007 Hispanic death rates do not include deaths from the District of Columbia, New Hampshire and North Dakota.

e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indian/Alaska Natives. The 1998-2007 Hispanic mortality trends do not include deaths from the District of Columbia, New Hampshire and North Dakota.

f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
Figure 1.12

By Cancer Site and Race/Ethnicity

### Incidence

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White</th>
<th>Black</th>
<th>Asian/Pacific Islander</th>
<th>Am. Indian/Alaska Nat.</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>63.8</td>
<td>73.5</td>
<td>38.7</td>
<td>45.3</td>
<td>32.1</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>47.4</td>
<td>58.9</td>
<td>39.2</td>
<td>42.1</td>
<td>37.3</td>
</tr>
<tr>
<td>Female Breast</td>
<td>126.5</td>
<td>118.3</td>
<td>90.0</td>
<td>76.4</td>
<td>86.0</td>
</tr>
<tr>
<td>Prostate</td>
<td>234.6</td>
<td>150.4</td>
<td>90.0</td>
<td>77.7</td>
<td>125.8</td>
</tr>
</tbody>
</table>

### Mortality

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White</th>
<th>Black</th>
<th>Asian/Pacific Islander</th>
<th>Am. Indian/Alaska Nat.</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>52.9</td>
<td>58.6</td>
<td>26.2</td>
<td>39.7</td>
<td>22.1</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.1</td>
<td>24.7</td>
<td>11.3</td>
<td>15.5</td>
<td>12.7</td>
</tr>
<tr>
<td>Female Breast</td>
<td>23.4</td>
<td>32.4</td>
<td>12.2</td>
<td>17.6</td>
<td>15.3</td>
</tr>
<tr>
<td>Prostate</td>
<td>22.8</td>
<td>54.2</td>
<td>10.6</td>
<td>20.0</td>
<td>18.8</td>
</tr>
</tbody>
</table>

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey) and US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

- Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
- Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky. Mortality data for Hispanics exclude cases from the District of Columbia, New Hampshire, and North Dakota.
SEER Incidence 1998-2007
Males by Race/Ethnicity

Figure 1.13

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
SEER Incidence 1998-2007
Females by Race/Ethnicity

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
**US Mortality 1998-2007**

**Males by Race/Ethnicity**

**Prostate**

**Lung and Bronchus**

**Colon and Rectum**


*Prostate* Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

*Hispanic* is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Mortality data for Hispanics excludes cases from the District of Columbia, Maine, Minnesota, New Hampshire, North Dakota, and Oklahoma.
Females by Race/Ethnicity


Mortality rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Mortality data for Hispanics excludes cases from the District of Columbia, Maine, Minnesota, New Hampshire, North Dakota, and Oklahoma.
### Table 2.15

**SEER Incidence and U.S. Mortality**

**Age-Adjusted Rates and Trends**

**By Race/Ethnicity and Sex**

#### SEER Incidence

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td><strong>SEER 17 Areas</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>461.6</td>
<td>538.9</td>
</tr>
<tr>
<td>White</td>
<td>469.2</td>
<td>541.5</td>
</tr>
<tr>
<td>White Hispanic*</td>
<td>347.8</td>
<td>399.6</td>
</tr>
<tr>
<td>White Non-Hispanic*</td>
<td>489.8</td>
<td>564.3</td>
</tr>
<tr>
<td>Black</td>
<td>489.8</td>
<td>624.0</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>310.8</td>
<td>346.5</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>317.7</td>
<td>335.8</td>
</tr>
<tr>
<td>Hispanic*</td>
<td>342.5</td>
<td>394.8</td>
</tr>
</tbody>
</table>

#### SEER 13 Areas

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td><strong>SEER 9 Areas</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>183.8</td>
<td>225.4</td>
</tr>
<tr>
<td>White</td>
<td>182.4</td>
<td>222.5</td>
</tr>
<tr>
<td>White Hispanic*</td>
<td>125.3</td>
<td>155.5</td>
</tr>
<tr>
<td>White Non-Hispanic*</td>
<td>186.7</td>
<td>227.5</td>
</tr>
<tr>
<td>Black</td>
<td>224.2</td>
<td>296.5</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>110.8</td>
<td>134.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total U.S.</td>
<td>123.2</td>
<td>145.1</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>156.7</td>
<td>183.7</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>81.8</td>
<td>98.3</td>
</tr>
<tr>
<td>Hispanic*</td>
<td>122.1</td>
<td>150.5</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.


Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

#### U.S. Mortality

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td><strong>SEER 17 Areas</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>110.8</td>
<td>156.7</td>
</tr>
<tr>
<td>White</td>
<td>114.5</td>
<td>151.5</td>
</tr>
<tr>
<td>White Hispanic*</td>
<td>84.0</td>
<td>99.6</td>
</tr>
<tr>
<td>White Non-Hispanic*</td>
<td>145.7</td>
<td>192.4</td>
</tr>
<tr>
<td>Black</td>
<td>145.7</td>
<td>192.4</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>106.0</td>
<td>136.5</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>106.0</td>
<td>136.5</td>
</tr>
<tr>
<td>Hispanic*</td>
<td>136.5</td>
<td>184.8</td>
</tr>
</tbody>
</table>


Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

The AAPC is significantly different from zero (p<0.05).
Incidence Mortality

Rate per 100,000 Rate per 100,000

Year of Diagnosis Year of Death

Joinpoint Analyses for Whites and Blacks from 1975-2007 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.


API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
### Table 3.15
Cancer of the Brain And Other Nervous System (Invasive)

<table>
<thead>
<tr>
<th>SEER Incidence</th>
<th>SEER 17 Areas[^b]</th>
<th>SEER 13 Areas[^b]</th>
<th>SEER 9 Areas[^b]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>6.5</td>
<td>7.6</td>
<td>5.5</td>
</tr>
<tr>
<td>White</td>
<td>7.1</td>
<td>8.4</td>
<td>6.0</td>
</tr>
<tr>
<td>White Hispanic[^e]</td>
<td>5.4</td>
<td>6.1</td>
<td>4.8</td>
</tr>
<tr>
<td>White Non-Hispanic[^e]</td>
<td>7.6</td>
<td>9.0</td>
<td>6.3</td>
</tr>
<tr>
<td>Black</td>
<td>4.0</td>
<td>4.7</td>
<td>3.5</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>3.5</td>
<td>4.0</td>
<td>3.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat[^f]</td>
<td>3.5</td>
<td>3.7</td>
<td>3.4</td>
</tr>
<tr>
<td>Hispanic[^e]</td>
<td>5.2</td>
<td>5.9</td>
<td>4.6</td>
</tr>
</tbody>
</table>

### U.S. Mortality[^g]

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>4.3</td>
<td>5.2</td>
<td>3.5</td>
</tr>
<tr>
<td>White</td>
<td>4.6</td>
<td>5.6</td>
<td>3.8</td>
</tr>
<tr>
<td>White Hispanic[^e]</td>
<td>2.9</td>
<td>3.4</td>
<td>2.5</td>
</tr>
<tr>
<td>White Non-Hispanic[^e]</td>
<td>4.8</td>
<td>5.8</td>
<td>3.9</td>
</tr>
<tr>
<td>Black</td>
<td>2.5</td>
<td>3.1</td>
<td>2.0</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.9</td>
<td>2.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat[^f]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total U.S.</td>
<td>1.7</td>
<td>2.2</td>
<td>1.4</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>2.1</td>
<td>2.7</td>
<td>1.6</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.3</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td>Hispanic[^e]</td>
<td>2.8</td>
<td>3.2</td>
<td>2.4</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates
Cancer of the Brain and Other Nervous System, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

a API = Asian/Pacific Islander.
b AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 4.19
Cancer of the Female Breast (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends\(^a\)
By Race/Ethnicity

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER U.S. Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 17 Areas(^b)</td>
<td>SEER 13 Areas(^b)</td>
</tr>
<tr>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Females</td>
<td>Females</td>
<td>Females</td>
</tr>
</tbody>
</table>

### SEER Incidence

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate per 100,000 persons</th>
<th>AAPC (%)</th>
<th>AAPC (%)</th>
<th>AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>122.9</td>
<td>-1.5*</td>
<td>-1.7*</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>126.5</td>
<td>-1.7*</td>
<td>-1.6*</td>
<td></td>
</tr>
<tr>
<td>White Hispanic(^e)</td>
<td>87.7</td>
<td>-1.1*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White Non-Hispanic(^e)</td>
<td>133.2</td>
<td>-1.6*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>118.3</td>
<td>-0.2</td>
<td>-0.3</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>90.0</td>
<td>-0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^f)</td>
<td>76.4</td>
<td>-0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic(^e)</td>
<td>86.0</td>
<td>-1.0*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### U.S. Mortality\(^g\)

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate per 100,000 persons</th>
<th>AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>Females</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>24.0</td>
<td>-1.9*</td>
</tr>
<tr>
<td>White</td>
<td>23.4</td>
<td>-2.0*</td>
</tr>
<tr>
<td>White Hispanic(^e)</td>
<td>15.8</td>
<td>-1.9*</td>
</tr>
<tr>
<td>White Non-Hispanic(^e)</td>
<td>23.9</td>
<td>-1.8*</td>
</tr>
<tr>
<td>Black</td>
<td>32.4</td>
<td>-1.6*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>12.2</td>
<td>-0.8*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^f)</td>
<td>Total U.S.</td>
<td>14.0</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>17.6</td>
<td>0.1</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>9.7</td>
<td>-2.4*</td>
</tr>
<tr>
<td>Hispanic(^e)</td>
<td>15.3</td>
<td>-1.9*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

* Statistic not shown. Rate based on less than 16 cases for the time interval.
* Trend based on less than 10 cases for at least one year within the time interval.
* The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
* The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
* The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
* Chamberlain was not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
* Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
* US Mortality Files, National Center for Health Statistics, CDC.
* The APC is significantly different from zero (p<.05)
The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Jointpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Trend based on less than 10 cases for at least one year within the time interval.


The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

Incidence data for Hispanic are based on NHIA and exclude cases from the Alaska Native Registry.

Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

The APC is significantly different from zero (p<.05).

### Table 4.20

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER 17 Areas</th>
<th>SEER 13 Areas</th>
<th>SEER 9 Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>All Races</td>
<td>30.0</td>
<td>0.8</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>30.5</td>
<td>0.0</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>White Hispanic</td>
<td>19.1</td>
<td>1.6*</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>32.7</td>
<td>0.5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>27.7</td>
<td>1.5*</td>
<td>1.6*</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>26.3</td>
<td>3.6</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>13.6</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>18.7</td>
<td>1.5*</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>
SEER Incidence and US Death Rates
Cancer of the Female Breast
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Rate per 100,000

Year of Diagnosis

White
Black
API
AI/AN
Hispanic

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 5.11
Cancer of the Cervix Uteri (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends\(^a\)
By Race/Ethnicity

<table>
<thead>
<tr>
<th>SEER Incidence</th>
<th>SEER 17 Areas(^b)</th>
<th>SEER 13 Areas(^b)</th>
<th>SEER 9 Areas(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate 2003-2007</td>
<td>Rate per 100,000 persons</td>
<td>Trend 1998-2007(^c)</td>
<td>Trend 1998-2007(^d)</td>
</tr>
<tr>
<td>Rate per 100,000 persons</td>
<td>Females</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Females</td>
<td>Females</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007</th>
<th>Trend 1998-2007(^h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Females</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Females</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007</th>
<th>Trend 1998-2007(^h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Females</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Females</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SEER Incidence

- **All Races**
  - Rate: 8.1 per 100,000 persons
  - Trend: -2.9*% (AAPC: -3.5*)

- **White**
  - Rate: 7.9 per 100,000 persons
  - Trends: -2.4*% (AAPC: -2.6*)
    - Sub-race:
      - **White Hispanic**
        - Rate: 12.4 per 100,000 persons
        - Trend: -5.8*% (AAPC: -3.5*)
      - **White Non-Hispanic**
        - Rate: 7.0 per 100,000 persons
        - Trend: -2.3*% (AAPC: -3.8*)

- **Black**
  - Rate: 10.1 per 100,000 persons
  - Trend: -5.0*% (AAPC: -3.8*)

- **Asian/Pacific Islander**
  - Rate: 7.5 per 100,000 persons
  - Trend: -4.6* (AAPC: -3.8*)

- **Amer Ind/Alaska Nat\(^e\)**
  - Rate: 7.7 per 100,000 persons
  - Trend: -1.9* (AAPC: -3.8*)

- **Hispanic\(^e\)**
  - Rate: 12.0 per 100,000 persons
  - Trend: -4.1* (AAPC: -3.8*)

### U.S. Mortality\(^g\)

- **All Races**
  - Rate: 2.4 per 100,000 persons
  - Trend: -2.4* (AAPC: -4.2*)

- **White**
  - Rate: 2.2 per 100,000 persons
  - Trend: -2.0* (AAPC: -2.8*)
    - Sub-race:
      - **White Hispanic**
        - Rate: 3.2 per 100,000 persons
        - Trend: -2.8* (AAPC: -2.1*)
      - **White Non-Hispanic**
        - Rate: 2.1 per 100,000 persons
        - Trend: -2.1* (AAPC: -2.1*)

- **Black**
  - Rate: 4.4 per 100,000 persons
  - Trend: -4.3* (AAPC: -3.8*)

- **Asian/Pacific Islander**
  - Rate: 2.1 per 100,000 persons
  - Trend: -3.7* (AAPC: -3.8*)

- **Amer Ind/Alaska Nat\(^e\)**
  - **Total U.S.**
    - Rate: 2.4 per 100,000 persons
    - Trend: -4.2* (AAPC: -3.5*)
  - **CHSDA Counties**
    - Rate: 3.4 per 100,000 persons
    - Trend: -3.5* (AAPC: -3.5*)
  - **Non-CHSDA Counties**
    - Rate: 1.1 per 100,000 persons
    - Trend: -2.7* (AAPC: -3.5*)

- **Hispanic\(^e\)**
  - Rate: 3.1 per 100,000 persons
  - Trend: -2.7* (AAPC: -2.7*)

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

---

The following abbreviations and notes are used:

- \(^a\) Statistic not shown. Rate based on less than 16 cases for the time interval.
- \(^b\) Trend based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- \(^c\) The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007.
- \(^d\) The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- \(^e\) Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
- \(^f\) Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- \(^g\) US Mortality Files, National Center for Health Statistics, CDC.
- \(^h\) The 1998-2007 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2007. The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\textsuperscript{a}  
Cancer of the Cervix Uteri  
Joinpoint Analyses for Whites and Blacks from 1975-2007  
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.  
\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.  
\textsuperscript{b} API = Asian/Pacific Islander.  
\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.  
\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 6.21
Cancer of the Colon and Rectum (Invasive)

SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends a
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER U.S. Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate 2003-2007</td>
<td>Rate 2003-2007</td>
</tr>
<tr>
<td></td>
<td>Total Males Females</td>
<td>Total Males Females</td>
</tr>
</tbody>
</table>

SEER Incidence

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate per 100,000 persons</th>
<th>Trend 1998-2007</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AAPC (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total Males Females</td>
<td></td>
</tr>
</tbody>
</table>

SEER 17 Areas

| All Races | 47.9 | 55.8 | 41.7 | -2.6* | -3.0* | -2.3* | -2.7* | -3.2* | -2.3* |
| White      | 47.4 | 55.4 | 40.9 | -2.8* | -3.2* | -2.5* | -2.8* | -3.3* | -2.6* |
| White Hispanic | 37.9 | 45.5 | 32.0 | -1.4* | -2.1* | -0.5* | - | - | - |
| White Non-Hispanic | 48.7 | 56.7 | 42.1 | -2.8* | -3.2* | -2.6* | - | - | - |
| Black      | 58.9 | 68.1 | 52.6 | -1.6* | -2.2* | -1.3* | -1.7* | -2.4* | -1.4* |
| Asian/Pacific Islander | 39.2 | 45.5 | 34.2 | -2.0* | -2.3* | -0.9* | - | - | - |
| Amer Ind/Alaska Nat | 42.1 | 43.4 | 40.4 | -0.3 | -0.9 | 0.2 | - | - | - |
| Hispanic   | 37.3 | 44.5 | 31.6 | -1.4* | -2.3* | -0.4* | - | - | - |

U.S. Mortality

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate per 100,000 persons</th>
<th>Trend 1998-2007</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AAPC (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total Males Females</td>
<td></td>
</tr>
</tbody>
</table>

SEER 13 Areas

| All Races | 17.6 | 21.2 | 14.9 | -2.6* | -2.8* | -2.6* |
| White      | 17.1 | 20.6 | 14.4 | -2.7* | -2.9* | -2.6* |
| White Hispanic | 16.1 | 16.1 | 10.8 | -1.8* | -2.5* | -1.6* |
| White Non-Hispanic | 17.4 | 20.9 | 14.6 | -2.5* | -2.8* | -2.4* |
| Black      | 24.7 | 30.5 | 21.0 | -2.2* | -1.9* | -2.5* |
| Asian/Pacific Islander | 11.3 | 13.2 | 9.9 | -2.2* | -2.4* | -1.8* |
| Amer Ind/Alaska Nat | Total U.S. | 11.9 | 14.7 | 9.8 | -3.0* | -3.2* | -1.8* |
| CHSDA Counties | 15.5 | 19.2 | 12.9 | -2.2* | -2.0 | -1.1 |
| Non-CHSDA Counties | 7.4 | 9.3 | 5.9 | -2.3* | -4.7 | -2.6* |
| Hispanic | 12.7 | 15.6 | 10.5 | -1.9* | -2.6* | -0.9* |

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

* Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
* The APC is significantly different from zero (p<.05).
Table 6.22  
Cancer of the Colon (Invasive) and Cancer of the Rectum (Invasive)  
SEER Incidence  
Age-Adjusted Rates and Trends*  
By Race/Ethnicity and Sex  

<table>
<thead>
<tr>
<th>Cancer of the Colon</th>
<th>SEER Incidence</th>
<th>SEER 17 Areasb</th>
<th>SEER 13 Areasb</th>
<th>SEER 9 Areasb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate 2003-2007</td>
<td>Trend 1998-2007c</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td>RACE/ETHNICITY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>34.5</td>
<td>38.9</td>
<td>31.2</td>
<td>-2.4*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>34.1</td>
<td>38.6</td>
<td>30.6</td>
<td>-2.8*</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>26.5</td>
<td>30.4</td>
<td>23.4</td>
<td>-1.1*</td>
</tr>
<tr>
<td>Black</td>
<td>35.1</td>
<td>39.7</td>
<td>31.5</td>
<td>-2.8*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>50.8</td>
<td>41.0</td>
<td>41.0</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>26.2</td>
<td>28.8</td>
<td>24.3</td>
<td>-2.3*</td>
</tr>
<tr>
<td>Hispanic</td>
<td>31.0</td>
<td>29.5</td>
<td>31.8</td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td>26.0</td>
<td>29.7</td>
<td>23.2</td>
<td>-1.1*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cancer of the Rectum</th>
<th>SEER Incidence</th>
<th>SEER 17 Areasb</th>
<th>SEER 13 Areasb</th>
<th>SEER 9 Areasb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate 2003-2007</td>
<td>Trend 1998-2007c</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td>RACE/ETHNICITY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>13.4</td>
<td>16.9</td>
<td>10.6</td>
<td>-2.6*</td>
</tr>
<tr>
<td>White</td>
<td>13.3</td>
<td>16.8</td>
<td>10.4</td>
<td>-3.0*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>11.5</td>
<td>15.1</td>
<td>8.5</td>
<td>-1.3*</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>13.6</td>
<td>17.1</td>
<td>10.7</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Black</td>
<td>14.0</td>
<td>17.2</td>
<td>11.6</td>
<td>-0.4</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>12.9</td>
<td>16.7</td>
<td>9.9</td>
<td>-1.0*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>11.1</td>
<td>13.9</td>
<td>8.7</td>
<td>-0.1</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11.3</td>
<td>14.8</td>
<td>8.5</td>
<td>-1.2*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. 

* Statistic not shown. Rate based on less than 16 cases for the time interval. 

+ Trend based on less than 10 cases for at least one year within the time interval. 


* The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/IA, Kentucky, Louisiana and New Jersey. 


| The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007. 

| Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. 

| Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. 

* The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates<sup>a</sup>
Cancer of the Colon and Rectum, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
## SEER Incidence and U.S. Mortality
### Age-Adjusted Rates and Trends
#### By Race/Ethnicity

**SEER Incidence**

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt; Rate 2003-2007 (per 100,000 persons)</th>
<th>SEER 13 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;c&lt;/sup&gt; AAPC (%)</th>
<th>SEER 9 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;d&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>23.5</td>
<td>-0.6*</td>
<td>-0.5*</td>
</tr>
<tr>
<td>White</td>
<td>24.4</td>
<td>-0.8*</td>
<td>-0.7*</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>18.0</td>
<td>0.6*</td>
<td>-</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>25.3</td>
<td>-0.8*</td>
<td>-</td>
</tr>
<tr>
<td>Black</td>
<td>20.6</td>
<td>1.5*</td>
<td>1.2*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>17.3</td>
<td>1.2*</td>
<td>-</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>16.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>17.6</td>
<td>0.7*</td>
<td>-</td>
</tr>
</tbody>
</table>

**U.S. Mortality**

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007 (per 100,000 persons)</th>
<th>Trend 1998-2007&lt;sup&gt;h&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>4.1</td>
<td>0.3*</td>
</tr>
<tr>
<td>White</td>
<td>3.9</td>
<td>-0.1</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>3.1</td>
<td>-0.4</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>3.9</td>
<td>-0.1</td>
</tr>
<tr>
<td>Black</td>
<td>7.2</td>
<td>0.4*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>2.5</td>
<td>1.3*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>2.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>Total U.S.</td>
<td>2.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>2.9</td>
<td>-</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.3</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>3.0</td>
<td>-0.3</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, National Cancer Institute. Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval. The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007. Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. US Mortality Files, National Center for Health Statistics, CDC. The 1998-2007 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2007. The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\textsuperscript{a}
Cancer of the Corpus and Uterus, NOS
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\textsuperscript{b} API = Asian/Pacific Islander.

\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 8.15
Cancer of the Esophagus (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER 17 Areas</th>
<th>SEER 13 Areas</th>
<th>SEER 9 Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td>All Races</td>
<td>4.5</td>
<td>7.8</td>
<td>1.9</td>
<td>-0.2</td>
</tr>
<tr>
<td>White</td>
<td>4.6</td>
<td>8.0</td>
<td>1.9</td>
<td>0.8*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>2.9</td>
<td>5.2</td>
<td>1.1</td>
<td>-1.8*</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>4.9</td>
<td>8.4</td>
<td>2.0</td>
<td>0.2</td>
</tr>
<tr>
<td>Black</td>
<td>5.4</td>
<td>8.9</td>
<td>2.9</td>
<td>-4.9*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>2.4</td>
<td>4.1</td>
<td>1.0</td>
<td>-1.5*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>4.0</td>
<td>5.2</td>
<td>2.9</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.9</td>
<td>5.1</td>
<td>1.1</td>
<td>-1.6*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>All Races</td>
<td>4.4</td>
<td>7.8</td>
</tr>
<tr>
<td>White</td>
<td>4.4</td>
<td>7.9</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>2.3</td>
<td>4.2</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>4.6</td>
<td>8.2</td>
</tr>
<tr>
<td>Black</td>
<td>5.1</td>
<td>8.9</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.9</td>
<td>3.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S.</td>
<td>2.9</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>3.8</td>
<td>6.4</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.8</td>
<td>2.9</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.2</td>
<td>4.0</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.


The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

US Mortality Files, National Center for Health Statistics, CDC.


The APC is significantly different from zero (p<.05).
Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
### Table 9.15

Hodgkin Lymphoma

SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>SEER Incidence</th>
<th>SEER 17 Areas</th>
<th>SEER 13 Areas</th>
<th>SEER 9 Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Rate per 100,000 persons</td>
<td>Total Males</td>
<td>Females</td>
<td>Total Males</td>
</tr>
<tr>
<td>All Races</td>
<td>2.8</td>
<td>3.2</td>
<td>2.5</td>
<td>0.8*</td>
</tr>
<tr>
<td>White</td>
<td>3.0</td>
<td>3.4</td>
<td>2.7</td>
<td>0.4</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>2.4</td>
<td>2.9</td>
<td>2.1</td>
<td>0.0</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>3.3</td>
<td>3.7</td>
<td>3.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Black</td>
<td>2.6</td>
<td>3.0</td>
<td>2.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.3</td>
<td>1.5</td>
<td>1.1</td>
<td>3.5*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>1.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.4</td>
<td>2.8</td>
<td>2.0</td>
<td>0.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Total Males</td>
<td>Females</td>
<td>Total Males</td>
</tr>
<tr>
<td>All Races</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>White</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>0.4</td>
<td>0.6</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>0.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Black</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>0.3</td>
<td>-</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.4</td>
<td>0.5</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\(^a\)
Hodgkin Lymphoma, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\(^a\) Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\(^b\) API = Asian/Pacific Islander.

\(^c\) AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\(^d\) Joinpoint could not fit a regression line for American Indian/Alaska Native Incidence due to insufficient data.

\(^e\) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 10.13
Kaposi Sarcoma
SEER Incidence
Age-Adjusted Rates and Trends
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt;</th>
<th>SEER 13 Areas&lt;sup&gt;b&lt;/sup&gt;</th>
<th>SEER 9 Areas&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>0.6</td>
<td>1.2</td>
<td>0.1</td>
</tr>
<tr>
<td>White</td>
<td>0.6</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.9</td>
<td>1.6</td>
<td>0.2</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.5</td>
<td>0.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Black</td>
<td>1.2</td>
<td>2.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.2</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.9</td>
<td>1.6</td>
<td>0.2</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- The APC is significantly different from zero (p<.05).
### Table 11.15
Cancer of the Kidney and Renal Pelvis (Invasive)

**SEER Incidence and U.S. Mortality**

**Age-Adjusted Rates and Trends**

By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>SEER Incidence</th>
<th>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt;</th>
<th>SEER 13 Areas&lt;sup&gt;c&lt;/sup&gt;</th>
<th>SEER 9 Areas&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate 2003-2007</td>
<td>Trend 1998-2007&lt;sup&gt;d&lt;/sup&gt;</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Rate per 100,000 persons</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
</tr>
<tr>
<td><strong>RACE/ETHNICITY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>14.1</td>
<td>19.2</td>
<td>9.9</td>
</tr>
<tr>
<td>White</td>
<td>14.5</td>
<td>19.7</td>
<td>10.2</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>13.8</td>
<td>18.1</td>
<td>10.3</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>14.7</td>
<td>20.1</td>
<td>10.2</td>
</tr>
<tr>
<td>Black</td>
<td>15.4</td>
<td>21.8</td>
<td>10.7</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7.3</td>
<td>10.2</td>
<td>5.1</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>17.4</td>
<td>21.2</td>
<td>14.1</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>13.3</td>
<td>17.5</td>
<td>10.0</td>
</tr>
</tbody>
</table>

| U.S. Mortality<sup>g</sup> | Rate 2003-2007 | Trend 1998-2007<sup>h</sup> | AAPC (%) | |
|---------------------------|----------------|---------------------------|---------| |
| Rate per 100,000 persons | Total Males Females | Total Males Females | | |
| **RACE/ETHNICITY** | | | |
| All Races | 4.1 | 5.9 | 2.7 | -0.4* | -0.8* | -0.6* | |
| White | 4.2 | 6.0 | 2.7 | -0.3* | -0.8* | -0.5* | |
| White Hispanic<sup>e</sup> | 3.8 | 5.4 | 2.5 | 0.1 | 0.1 | -0.2 | |
| White Non-Hispanic<sup>e</sup> | 4.2 | 6.0 | 2.8 | -0.3* | -0.8* | -0.5* | |
| Black | 4.0 | 6.0 | 2.7 | -0.3 | -0.3 | -0.5 | |
| Asian/Pacific Islander | 1.8 | 2.6 | 1.2 | 0.2 | -0.3 | 0.4 | |
| Amer Ind/Alaska Nat<sup>f</sup> | | | | |
| Total U.S. | 4.4 | 6.5 | 2.7 | -0.8 | -0.1 | -2.6* | |
| CHSDA Counties | 6.0 | 8.8 | 3.8 | -0.4 | 0.0 | -1.7 | |
| Non-CHSDA Counties | 2.4 | 3.7 | 1.4 | - | - | - | |
| Hispanic<sup>e</sup> | 3.6 | 5.2 | 2.4 | 0.1 | 0.1 | -0.1 | |

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.


The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1975-2007.

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

US Mortality Files, National Center for Health Statistics, CDC.


The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\(^a\)
Cancer of the Kidney and Renal Pelvis, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\(a\) Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
\(b\) API = Asian/Pacific Islander.
\(c\) AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
\(d\) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
## Table 12.15
Cancer of the Larynx (Invasive)

### SEER Incidence and U.S. Mortality Age-Adjusted Rates and Trends

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER U.S. Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>All Races</td>
<td>3.4 6.1 1.3</td>
<td>-3.0* -3.1* -3.1*</td>
</tr>
<tr>
<td>White</td>
<td>3.4 6.1 1.3</td>
<td>-2.8* -2.9* -2.7*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>2.4 4.7 0.6</td>
<td>-2.5* -2.5* -</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>3.6 6.3 1.4</td>
<td>-2.7* -2.9* -2.5*</td>
</tr>
<tr>
<td>Black</td>
<td>5.4 10.3 1.9</td>
<td>-3.3* -3.3* -3.3*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.2 2.4 0.3</td>
<td>-3.8* -3.5* -</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>1.5 2.4 -</td>
<td>- - -</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.4 4.6 0.6</td>
<td>-2.4* -2.4* -</td>
</tr>
</tbody>
</table>

### U.S. Mortality

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>All Races</td>
<td>1.2 2.2 0.5</td>
<td>-2.1* -2.4* -1.9*</td>
</tr>
<tr>
<td>White</td>
<td>1.1 2.0 0.4</td>
<td>-1.9* -2.3* -1.5*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>0.9 1.9 0.2</td>
<td>-3.9* -3.2* -</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>1.2 2.1 0.5</td>
<td>-1.6* -2.0* -1.1*</td>
</tr>
<tr>
<td>Black</td>
<td>2.3 4.6 0.7</td>
<td>-3.0* -2.9* -3.2*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.4 0.8 0.1</td>
<td>-2.5* -1.7* -</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S. 0.9 1.6 0.3</td>
<td>-</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>0.9 1.9 -</td>
<td>-</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>0.8 1.2 -</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.9 1.8 0.1</td>
<td>-3.0* -3.2* -</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Statistic not shown. Rate based on less than 16 cases for the time interval. Trends based on less than 10 cases for at least one year within the time interval. The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007. Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties. US Mortality Files, National Center for Health Statistics, CDC. The 1998-2007 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2007. The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates
Cancer of the Larynx, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.
b API = Asian/Pacific Islander.
c AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
d Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
### Table 13.23

**Leukemia**

**SEER Incidence**

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt; Rate 2003-2007 Rate per 100,000 persons</th>
<th>SEER 13 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;c&lt;/sup&gt; AAPC (%)</th>
<th>SEER 9 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;d&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Males</td>
<td>Total Females</td>
<td>Total Males</td>
</tr>
<tr>
<td>All Races</td>
<td>12.3</td>
<td>15.8</td>
<td>9.6</td>
</tr>
<tr>
<td>White</td>
<td>12.9</td>
<td>16.6</td>
<td>10.0</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>9.7</td>
<td>11.5</td>
<td>8.2</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>13.2</td>
<td>17.1</td>
<td>10.2</td>
</tr>
<tr>
<td>Black</td>
<td>9.8</td>
<td>12.7</td>
<td>7.8</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7.2</td>
<td>8.8</td>
<td>6.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>6.5</td>
<td>7.2</td>
<td>5.9</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>9.5</td>
<td>11.2</td>
<td>8.0</td>
</tr>
</tbody>
</table>

**U.S. Mortality<sup>g</sup>**

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007&lt;sup&gt;h&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Males</td>
<td>Total Females</td>
</tr>
<tr>
<td>All Races</td>
<td>7.2</td>
<td>9.7</td>
</tr>
<tr>
<td>White</td>
<td>7.4</td>
<td>10.0</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5.0</td>
<td>6.3</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>7.5</td>
<td>10.2</td>
</tr>
<tr>
<td>Black</td>
<td>6.3</td>
<td>8.4</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>3.8</td>
<td>4.9</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Total U.S.</td>
<td>3.6</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>4.8</td>
<td>5.8</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>2.1</td>
<td>2.2</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.8</td>
<td>6.0</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.


The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic cancer death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

US Mortality Files, National Center for Health Statistics, CDC.


The APC is significantly different from zero (p<0.05).
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

SEER Incidence and US Death Rates
Leukemia, Both Sexes

Incidence

Mortality

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.
a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.
b API = Asian/Pacific Islander.
c AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
d Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
# Table 14.15
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends\(^a\)
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas(^b) Rate 2003-2007 Rate per 100,000 persons</th>
<th>SEER 13 Areas(^b) Trend 1998-2007(^c) AAPC (%)</th>
<th>SEER 9 Areas(^b) Trend 1998-2007(^d) AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>6.9 10.7 3.7</td>
<td>2.6* 3.2* 1.5*</td>
<td>2.7* 3.5* 1.7*</td>
</tr>
<tr>
<td>White</td>
<td>5.9 9.1 3.1</td>
<td>2.7 3.3* 1.0*</td>
<td>2.5* 3.2* 0.7</td>
</tr>
<tr>
<td>White Hispanic(^e)</td>
<td>10.7 16.0 6.1</td>
<td>2.5* 2.3* 2.3*</td>
<td>– – –</td>
</tr>
<tr>
<td>White Non-Hispanic(^e)</td>
<td>5.1 8.0 2.7</td>
<td>2.3 3.0* 0.6</td>
<td>– – –</td>
</tr>
<tr>
<td>Black</td>
<td>8.6 14.0 4.4</td>
<td>3.7* 4.0* 2.6*</td>
<td>3.1* 3.3* 2.6*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>14.4 21.7 8.3</td>
<td>0.8* 0.9* 0.7</td>
<td>– – –</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^f)</td>
<td>10.6 14.6 6.9</td>
<td>0.9 – –</td>
<td>– – –</td>
</tr>
<tr>
<td>Hispanic(^e)</td>
<td>10.5 15.6 6.0</td>
<td>2.7* 2.4* 2.4*</td>
<td>– – –</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. Mortality(^g)</th>
<th>Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007(^h) AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>5.2 7.7 3.2</td>
<td>2.0* 2.1* 1.3*</td>
</tr>
<tr>
<td>White</td>
<td>4.8 7.0 3.0</td>
<td>2.1* 2.2* 1.4*</td>
</tr>
<tr>
<td>White Hispanic(^e)</td>
<td>8.3 11.8 5.4</td>
<td>1.5* 1.4* 1.5*</td>
</tr>
<tr>
<td>White Non-Hispanic(^e)</td>
<td>4.5 6.6 2.8</td>
<td>2.0* 2.1* 1.1*</td>
</tr>
<tr>
<td>Black</td>
<td>7.0 11.1 3.9</td>
<td>1.7* 2.2* 0.6</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>10.1 14.7 6.4</td>
<td>-0.9* -1.0* -0.6</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^f)</td>
<td>Total U.S. 6.4</td>
<td>1.8* 1.2 1.9</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>8.6 10.9 6.6</td>
<td>1.9* 1.4 2.1</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>3.6 5.0 2.3</td>
<td>– – –</td>
</tr>
<tr>
<td>Hispanic(^e)</td>
<td>8.0 11.3 5.2</td>
<td>1.6* 1.3* 1.4*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates
Cancer of the Liver and Intrahepatic Bile Duct, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Incidence
Rate per 100,000
Year of Diagnosis
White
Black
API
AI/AN
Hispanic

Mortality
Rate per 100,000
Year of Death
White
Black
API
AI/AN
Hispanic

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 15.21
Lung and Bronchus (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trendsa
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>Total 62.5 Males 76.2 Females</td>
<td>Total -1.2 Males -2.1 Females</td>
<td>Total -0.8 Males -2.0 Females</td>
</tr>
<tr>
<td>White</td>
<td>Total 63.8 Males 76.3 Females</td>
<td>Total -1.4 Males -2.1 Females</td>
<td>Total -1.1 Males -2.2 Females</td>
</tr>
<tr>
<td>Hispanic</td>
<td>Total 32.7 Males 42.1 Females</td>
<td>Total -1.8 Males -2.5 Females</td>
<td>Total -1.1 Males -2.2 Females</td>
</tr>
<tr>
<td>Black</td>
<td>Total 73.5 Males 101.2 Females</td>
<td>Total -1.5 Males -2.8 Females</td>
<td>Total -2.0 Males -3.4 Females</td>
</tr>
<tr>
<td>Asian/Pacific</td>
<td>Total 38.7 Males 52.9 Females</td>
<td>Total -1.2 Males -1.2 Females</td>
<td>Total -2.0 Males -3.4 Females</td>
</tr>
<tr>
<td>Amer Ind/Alaska</td>
<td>Total 45.3 Males 52.7 Females</td>
<td>Total -0.5 Males -2.1 Females</td>
<td>Total -2.0 Males -3.4 Females</td>
</tr>
<tr>
<td>Hispanic</td>
<td>Total 32.1 Males 41.4 Females</td>
<td>Total -1.7 Males -2.3 Females</td>
<td>Total -2.0 Males -3.4 Females</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>Total 52.5 Males 68.8 Females</td>
</tr>
<tr>
<td>White</td>
<td>Total 52.9 Males 68.3 Females</td>
</tr>
<tr>
<td>Hispanic</td>
<td>Total 22.8 Males 33.4 Females</td>
</tr>
<tr>
<td>Black</td>
<td>Total 55.4 Males 71.1 Females</td>
</tr>
<tr>
<td>Asian/Pacific</td>
<td>Total 58.6 Males 87.5 Females</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total 26.2 Males 36.7 Females</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>Total 39.7 Males 48.1 Females</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>Total 26.4 Males 32.5 Females</td>
</tr>
<tr>
<td>Hispanic</td>
<td>Total 22.1 Males 32.5 Females</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
- Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
- Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\textsuperscript{a}
Cancer of the Lung and Bronchus, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Incidence and Mortality Rates per 100,000

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\textsuperscript{b} API = Asian/Pacific Islander.
\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 16.15
Melanoma of the Skin (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends by Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>SEER Incidence</th>
<th>SEER 17 Areas</th>
<th>SEER 13 Areas</th>
<th>SEER 9 Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>RACE/ETHNICITY</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
</tr>
<tr>
<td>All Races</td>
<td>20.1 25.6 16.2</td>
<td>1.6* 1.7* 1.5*</td>
<td>2.6* 2.0* 2.3*</td>
</tr>
<tr>
<td>White</td>
<td>23.5 29.7 19.1</td>
<td>2.6* 2.6* 2.0*</td>
<td>2.1* 2.2* 2.3*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>4.5 4.4 4.8</td>
<td>-0.8 1.3 0.7</td>
<td>- - -</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>27.4 34.3 22.6</td>
<td>3.1* 3.1* 3.2*</td>
<td>- - -</td>
</tr>
<tr>
<td>Black</td>
<td>1.0 1.1 1.0</td>
<td>-3.5* - -</td>
<td>-0.3 0.2 -0.7</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.4 1.6 1.3</td>
<td>1.4 1.6 1.4</td>
<td>- - -</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>3.8 4.1 3.7</td>
<td>- - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Hispanic</td>
<td>4.5 4.4 4.7</td>
<td>-1.0 1.1 0.6</td>
<td>- - -</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>RACE/ETHNICITY</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
</tr>
<tr>
<td>All Races</td>
<td>2.7 4.0 1.7</td>
<td>-0.1 0.2 -0.6*</td>
</tr>
<tr>
<td>White</td>
<td>3.1 4.5 2.0</td>
<td>0.1 0.3* -0.4*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>0.8 1.0 0.6</td>
<td>-0.6 -0.3 -0.9</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>3.3 4.8 2.1</td>
<td>0.3* 0.5* -0.2</td>
</tr>
<tr>
<td>Black</td>
<td>0.4 0.5 0.4</td>
<td>-0.9 0.4 -1.7</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.4 0.4 0.3</td>
<td>-0.6 - -</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>- - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Total U.S.</td>
<td>0.8 1.1 0.6</td>
<td>- - -</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>1.1 1.6 0.8</td>
<td>- - -</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>0.5 - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.7 1.0 0.6</td>
<td>-0.5 -0.4 -0.7</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval. The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007. Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.  The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties. US Mortality Files, National Center for Health Statistics, CDC. The 1998-2007 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2007. The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\textsuperscript{a}
Melanoma of the Skin, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\textsuperscript{b} API = Asian/Pacific Islander.

\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
## Table 17.11
Malignant Mesothelioma

SEER Incidence
Age-Adjusted Rates and Trends\(^a\)
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas(^b)</th>
<th>SEER 13 Areas(^c)</th>
<th>SEER 9 Areas(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>All Races</td>
<td>1.1 1.9 0.4</td>
<td>-1.1* -1.6* 1.0</td>
<td>-1.2* -1.8* 0.0</td>
</tr>
<tr>
<td>White</td>
<td>1.2 2.1 0.5</td>
<td>-0.7* -1.3* 0.8*</td>
<td>-0.7 -1.5* 0.9*</td>
</tr>
<tr>
<td>White Hispanic(^e)</td>
<td>1.0 1.6 0.5</td>
<td>-2.5* -3.2* -</td>
<td>- - -</td>
</tr>
<tr>
<td>White Non-Hispanic(^e)</td>
<td>1.2 2.2 0.5</td>
<td>-0.6* -1.1* 0.6</td>
<td>- - -</td>
</tr>
<tr>
<td>Black</td>
<td>0.6 1.2 0.3</td>
<td>- - -</td>
<td>-7.0* -7.9* -</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.4 0.6 0.2</td>
<td>- - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^f)</td>
<td>0.8 - -</td>
<td>- - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Hispanic(^e)</td>
<td>0.9 1.5 0.5</td>
<td>-2.3* -3.0* -</td>
<td>- - -</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

\(^a\) Statistic not shown. Rate based on less than 16 cases for the time interval.

\(^b\) Trend based on less than 10 cases for at least one year within the time interval.


\(^d\) The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

\(^e\) The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

\(^f\) The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.

\(^g\) The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007.

\(^h\) The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.

\(^i\) Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

\(^j\) Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\(^k\) The APC is significantly different from zero (p<.05).
### Table 18.15

**Myeloma**

**SEER Incidence and U.S. Mortality**

**Age-Adjusted Rates and Trends**

**By Race/Ethnicity and Sex**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td><strong>SEER Incidence</strong></td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>All Races</td>
<td>5.6</td>
<td>7.1</td>
</tr>
<tr>
<td>White</td>
<td>5.2</td>
<td>6.7</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>5.4</td>
<td>6.4</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>5.2</td>
<td>6.7</td>
</tr>
<tr>
<td>Black</td>
<td>11.7</td>
<td>14.3</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>3.3</td>
<td>4.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>4.5</td>
<td>4.8</td>
</tr>
<tr>
<td>Hispanic</td>
<td>5.3</td>
<td>6.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td><strong>RACE/ETHNICITY</strong></td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>All Races</td>
<td>3.6</td>
<td>4.4</td>
</tr>
<tr>
<td>White</td>
<td>3.3</td>
<td>4.2</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>2.9</td>
<td>3.4</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>3.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Black</td>
<td>6.7</td>
<td>8.1</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.7</td>
<td>2.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S.</td>
<td>2.7</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>3.5</td>
<td>4.2</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.8</td>
<td>2.2</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.9</td>
<td>3.3</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 19.19
Non-Hodgkin Lymphoma
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trendsa
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007 AAPC (%)</th>
<th>SEER U.S. Mortality Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007 AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 17 Areasb</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>19.6</td>
<td>23.6</td>
<td>16.5</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>20.5</td>
<td>24.6</td>
<td>17.2</td>
<td></td>
</tr>
<tr>
<td>White Hispanicc</td>
<td>16.8</td>
<td>19.2</td>
<td>14.8</td>
<td></td>
</tr>
<tr>
<td>White Non-Hispanicc</td>
<td>21.1</td>
<td>25.5</td>
<td>17.6</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>14.7</td>
<td>17.8</td>
<td>12.3</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>12.9</td>
<td>15.7</td>
<td>10.8</td>
<td></td>
</tr>
<tr>
<td>Amer Ind/Alaska Natc</td>
<td>11.4</td>
<td>12.5</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>Hispanicc</td>
<td>16.5</td>
<td>18.7</td>
<td>14.5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. Mortalityg</th>
<th>Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007 AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 17 Areasb</td>
<td>Total</td>
</tr>
<tr>
<td>All Races</td>
<td>6.9</td>
<td>8.7</td>
</tr>
<tr>
<td>White</td>
<td>7.2</td>
<td>9.1</td>
</tr>
<tr>
<td>White Hispanicc</td>
<td>5.5</td>
<td>6.6</td>
</tr>
<tr>
<td>White Non-Hispanicc</td>
<td>7.3</td>
<td>9.2</td>
</tr>
<tr>
<td>Black</td>
<td>4.8</td>
<td>6.0</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>4.4</td>
<td>5.5</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S.</td>
<td>3.8</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>4.9</td>
<td>5.3</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>2.4</td>
<td>3.2</td>
</tr>
<tr>
<td>Hispanicc</td>
<td>5.3</td>
<td>6.3</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates for Non-Hodgkin Lymphoma, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
### Table 20.19
Cancer of the Oral Cavity and Pharynx (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends
By Race/Ethnicity and Sex

#### SEER Incidence

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007</th>
<th>Trend 1998-2007</th>
<th>AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>APCR (%)</td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>10.4</td>
<td>15.4</td>
<td>6.1</td>
</tr>
<tr>
<td>White</td>
<td>10.5</td>
<td>15.7</td>
<td>6.1</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>6.0</td>
<td>8.8</td>
<td>3.7</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>11.3</td>
<td>16.9</td>
<td>6.5</td>
</tr>
<tr>
<td>Black</td>
<td>10.2</td>
<td>16.1</td>
<td>5.8</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7.6</td>
<td>10.5</td>
<td>5.3</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>7.3</td>
<td>9.6</td>
<td>5.2</td>
</tr>
<tr>
<td>Hispanic</td>
<td>5.9</td>
<td>8.7</td>
<td>3.6</td>
</tr>
</tbody>
</table>

#### U.S. Mortality

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007</th>
<th>Trend 1998-2007</th>
<th>AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>APCR (%)</td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>2.5</td>
<td>3.9</td>
<td>1.4</td>
</tr>
<tr>
<td>White</td>
<td>2.4</td>
<td>3.7</td>
<td>1.4</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>1.6</td>
<td>2.5</td>
<td>0.8</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>2.5</td>
<td>3.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Black</td>
<td>3.6</td>
<td>6.3</td>
<td>1.5</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>2.1</td>
<td>3.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>1.9</td>
<td>2.9</td>
<td>1.2</td>
</tr>
<tr>
<td>Total U.S.</td>
<td>2.4</td>
<td>3.5</td>
<td>1.6</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>1.3</td>
<td>2.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.5</td>
<td>2.5</td>
<td>0.8</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
SEER Incidence and US Death Rates
Cancer of the Oral Cavity and Pharynx, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
SEER Incidence Rates\textsuperscript{a}

Cancer of the Oral Cavity and Pharyngeal for Selected Subsites, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints. Regression lines could not be calculated for data series that had at least one diagnosis year with a 0 case count.

\textsuperscript{b} API = Asian/Pacific Islander.

\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
### Table 21.11
Cancer of the Ovary (Invasive)

#### SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends\(^a\)
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence Rate 2003-2007 per 100,000 persons</th>
<th>Trend 1998-2007b AAPC (%)</th>
<th>Trend 1998-2007d AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>12.9</td>
<td>-1.5*</td>
<td>-1.7*</td>
</tr>
<tr>
<td>White</td>
<td>13.5</td>
<td>-1.7*</td>
<td>-1.9*</td>
</tr>
<tr>
<td>White Hispanic(\text{c})</td>
<td>11.3</td>
<td>-0.9</td>
<td>-</td>
</tr>
<tr>
<td>White Non-Hispanic(\text{c})</td>
<td>13.9</td>
<td>-1.6*</td>
<td>-</td>
</tr>
<tr>
<td>Black</td>
<td>10.2</td>
<td>-0.5</td>
<td>-0.5*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>9.8</td>
<td>0.0</td>
<td>-</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(\text{f})</td>
<td>10.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic(\text{e})</td>
<td>11.0</td>
<td>-0.7</td>
<td>-</td>
</tr>
</tbody>
</table>

#### U.S. Mortality\(\text{g}\)
Rate 2003-2007 per 100,000 persons
Females

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>Rate 2003-2007 per 100,000 persons</th>
<th>Trend 1998-2007h AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
<td>8.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>White</td>
<td>8.9</td>
<td>-0.5</td>
</tr>
<tr>
<td>White Hispanic(\text{c})</td>
<td>6.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>White Non-Hispanic(\text{c})</td>
<td>9.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>Black</td>
<td>7.2</td>
<td>-1.6</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>4.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat Total U.S.</td>
<td>5.3</td>
<td>-0.2</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>6.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>3.5</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic(\text{e})</td>
<td>6.0</td>
<td>-0.4</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\textsuperscript{a}
Cancer of the Ovary
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473. Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 22.15
Cancer of the Pancreas (Invasive)
SEER Incidence and U.S. Mortality Age-Adjusted Rates and Trends\(^{a}\)
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Males Females</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>All Races</td>
<td>11.7 13.3 10.5</td>
<td>0.4* 0.2* 0.4*</td>
</tr>
<tr>
<td>White</td>
<td>11.6 13.2 10.3</td>
<td>0.5* 0.5* 0.5*</td>
</tr>
<tr>
<td>White Hispanic(^{c})</td>
<td>10.7 11.3 10.2</td>
<td>0.0 -0.1 0.1</td>
</tr>
<tr>
<td>White Non-Hispanic(^{c})</td>
<td>11.8 13.5 10.3</td>
<td>0.6* 0.6* 0.5*</td>
</tr>
<tr>
<td>Black</td>
<td>15.5 16.7 14.4</td>
<td>-0.8* -1.2* -0.6</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>9.1 10.2 8.3</td>
<td>0.2 -0.5 0.9*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat(^{f})</td>
<td>10.3 10.6 10.1</td>
<td>- - -</td>
</tr>
<tr>
<td>Hispanic(^{e})</td>
<td>10.5 10.9 10.1</td>
<td>0.1 0.0 0.2</td>
</tr>
<tr>
<td>U.S. Mortality(^{g})</td>
<td>Rate 2003-2007</td>
<td>Trend 1998-2007(^{h})</td>
</tr>
<tr>
<td></td>
<td>Total Males Females</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>All Races</td>
<td>10.7 12.3 9.4</td>
<td>0.3* 0.3* 0.3*</td>
</tr>
<tr>
<td>White</td>
<td>10.5 12.2 9.1</td>
<td>0.4* 0.4* 0.2*</td>
</tr>
<tr>
<td>White Hispanic(^{c})</td>
<td>10.5 9.4 7.8</td>
<td>-0.4 -0.5* 0.2*</td>
</tr>
<tr>
<td>White Non-Hispanic(^{c})</td>
<td>10.7 12.4 9.2</td>
<td>0.6* 0.6* 0.3*</td>
</tr>
<tr>
<td>Black</td>
<td>13.8 15.4 12.4</td>
<td>-0.7* -1.0* -0.1*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7.4 8.2 6.9</td>
<td>-0.2 -0.9* 0.4*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S.</td>
<td>6.8 7.4 6.4</td>
</tr>
<tr>
<td></td>
<td>CHSDA Counties</td>
<td>8.8 9.9 8.0</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>4.4 4.3 4.4</td>
<td>-1.3 - -</td>
</tr>
<tr>
<td>Hispanic(^{e})</td>
<td>8.3 9.1 7.5</td>
<td>-0.5 -0.5* 0.2*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).

National Cancer Institute
SEER Incidence and US Death Rates\textsuperscript{a}
Cancer of the Pancreas, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\textsuperscript{a} Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\textsuperscript{b} API = Asian/Pacific Islander.

\textsuperscript{c} AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

\textsuperscript{d} Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 23.11

Cancer of the Prostate (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trendsa
By Race/Ethnicity

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER 17 Areasb</th>
<th>SEER 13 Areasc</th>
<th>SEER 9 Areasb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Males</td>
<td>Males</td>
<td>Males</td>
<td>Males</td>
<td>Males</td>
</tr>
<tr>
<td>All Races</td>
<td>156.9</td>
<td>-1.4*</td>
<td>-1.1*</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>150.4</td>
<td>-1.5*</td>
<td>-1.3*</td>
<td></td>
</tr>
<tr>
<td>White Hispanic</td>
<td>124.5</td>
<td>-2.8*</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>154.4</td>
<td>-1.4*</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>234.6</td>
<td>-2.6*</td>
<td>-2.1*</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>90.0</td>
<td>-0.6</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>77.7</td>
<td>-2.3*</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>125.8</td>
<td>-2.3*</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>Males</td>
<td>Males</td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>24.7</td>
<td>-4.0*</td>
</tr>
<tr>
<td>White</td>
<td>22.8</td>
<td>-3.7*</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>19.2</td>
<td>-3.2*</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>22.9</td>
<td>-3.7*</td>
</tr>
<tr>
<td>Black</td>
<td>54.2</td>
<td>-4.0*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>10.6</td>
<td>-4.1*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>16.3</td>
<td>-3.9*</td>
</tr>
<tr>
<td>Total U.S.</td>
<td>16.3</td>
<td>-3.9*</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>20.0</td>
<td>-2.9*</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>11.6</td>
<td>-5.0*</td>
</tr>
<tr>
<td>Hispanic</td>
<td>18.8</td>
<td>-3.6*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.


The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic incidence trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

US Mortality Files, National Center for Health Statistics, CDC.


The APC is significantly different from zero (p<.05).
Joinpoint Analyses for Whites and Blacks from 1975-2007 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

**Source:** Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

**a** Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

**b** API = Asian/Pacific Islander.

**c** AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

**d** Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

---

**Figure 23.3**

**SEER Incidence and US Death Rates**

**Cancer of the Prostate**

Joinpoint Analyses for Whites and Blacks from 1975-2007 and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

---

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>Incidence Rate per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year of Death</th>
<th>Mortality Rate per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
</tr>
</tbody>
</table>
Table 24.15
Cancer of the Stomach (Invasive)
SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>SEER Incidence</th>
<th>SEER 17 Areas</th>
<th>SEER 13 Areas</th>
<th>SEER 9 Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Rate per 100,000 persons</td>
<td>Total Males</td>
<td>Total Females</td>
</tr>
<tr>
<td>All Races</td>
<td>7.8</td>
<td>10.9</td>
<td>5.5</td>
</tr>
<tr>
<td>White</td>
<td>6.8</td>
<td>9.6</td>
<td>4.7</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>11.8</td>
<td>15.2</td>
<td>9.3</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>6.1</td>
<td>8.8</td>
<td>3.9</td>
</tr>
<tr>
<td>Black</td>
<td>11.9</td>
<td>16.7</td>
<td>8.6</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>13.2</td>
<td>17.5</td>
<td>10.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>10.9</td>
<td>15.5</td>
<td>7.3</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11.6</td>
<td>14.8</td>
<td>9.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate per 100,000 persons</td>
<td>Rate per 100,000 persons</td>
<td>Total Males</td>
<td>Total Females</td>
</tr>
<tr>
<td>All Races</td>
<td>3.8</td>
<td>5.3</td>
<td>2.7</td>
</tr>
<tr>
<td>White</td>
<td>3.3</td>
<td>4.6</td>
<td>2.4</td>
</tr>
<tr>
<td>White Hispanic</td>
<td>6.2</td>
<td>8.2</td>
<td>4.8</td>
</tr>
<tr>
<td>White Non-Hispanic</td>
<td>3.1</td>
<td>4.3</td>
<td>2.1</td>
</tr>
<tr>
<td>Black</td>
<td>7.3</td>
<td>10.7</td>
<td>5.0</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>7.2</td>
<td>9.4</td>
<td>5.6</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat</td>
<td>Total U.S.</td>
<td>4.3</td>
<td>6.2</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>6.3</td>
<td>9.2</td>
<td>4.2</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.8</td>
<td>2.6</td>
<td>1.2</td>
</tr>
<tr>
<td>Hispanic</td>
<td>6.0</td>
<td>8.0</td>
<td>4.6</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.
- Trend based on less than 10 cases for at least one year within the time interval.
- The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
- The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
- The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
- The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
- Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- US Mortality Files, National Center for Health Statistics, CDC.
- The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates\(^a\)
Cancer of the Stomach, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

\(^a\) Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

\(^b\) API = Asian/Pacific Islander.
\(^c\) AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
\(^d\) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

---

**Incidence**

- **White**
- **Black**
- **API**
- **AI/AN**
- **Hispanic**

**Mortality**

- **White**
- **Black**
- **API**
- **AI/AN**
- **Hispanic**

*Figure 24.2*
### Table 25.11
Cancer of the Testis (Invasive)

**SEER Incidence and U.S. Mortality**

**Age-Adjusted Rates and Trends**

**By Race/Ethnicity**

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER Incidence</th>
<th>SEER Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt;</td>
<td>SEER 13 Areas&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>All Races</td>
<td>5.4</td>
<td>1.1&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>White</td>
<td>6.4</td>
<td>1.3&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.2</td>
<td>2.0&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>7.2</td>
<td>1.6&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>Black</td>
<td>1.2</td>
<td>-0.5</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.8</td>
<td>1.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>4.3</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.0</td>
<td>3.2&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

* Statistic not shown. Rate based on less than 16 cases for the time interval.
* Trend based on less than 10 cases for at least one year within the time interval.
* The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
* The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
* The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
* The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
* Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
* Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
* The SEER 9 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
* The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
* The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
* Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
* Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
* The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates<sup>a</sup>
Cancer of the Testis
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

<sup>a</sup> Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

<sup>b</sup> API = Asian/Pacific Islander.

<sup>c</sup> AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>d</sup> Joinpoint could not fit a regression line for American Indian/Alaska Native Mortality due to insufficient data.

<sup>e</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 26.15
Cancer of the Thyroid (Invasive)
SEER Incidence and U.S. Mortality Age-Adjusted Rates and Trendsa
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 100,000 persons</td>
<td>AAPC (%)</td>
<td>Total Males Females</td>
<td>Total Males Females</td>
</tr>
<tr>
<td>All Races</td>
<td>10.2</td>
<td>5.2</td>
<td>15.2</td>
<td>6.1*</td>
</tr>
<tr>
<td>White</td>
<td>10.7</td>
<td>5.5</td>
<td>16.0</td>
<td>6.3*</td>
</tr>
<tr>
<td>White Hispanicc</td>
<td>8.6</td>
<td>3.7</td>
<td>13.6</td>
<td>4.5*</td>
</tr>
<tr>
<td>White Non-Hispanicc</td>
<td>11.5</td>
<td>6.0</td>
<td>16.9</td>
<td>6.6*</td>
</tr>
<tr>
<td>Black</td>
<td>6.2</td>
<td>3.0</td>
<td>9.2</td>
<td>6.5*</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>10.1</td>
<td>4.4</td>
<td>15.2</td>
<td>4.6*</td>
</tr>
<tr>
<td>Amer Ind/Alaska Natc</td>
<td>5.8</td>
<td>3.1</td>
<td>8.9</td>
<td>2.1</td>
</tr>
<tr>
<td>Hispanic</td>
<td>8.4</td>
<td>3.6</td>
<td>13.3</td>
<td>4.6*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. Mortalityg</th>
<th>Rate 2003-2007</th>
<th>Trend 1998-2007h</th>
<th>Rate per 100,000 persons</th>
<th>AAPC (%)</th>
<th>Total Males Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total Males Females</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Races</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.6*</td>
<td>1.6*</td>
</tr>
<tr>
<td>White</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.6*</td>
<td>1.6*</td>
</tr>
<tr>
<td>White Hispanicc</td>
<td>0.6</td>
<td>0.5</td>
<td>0.6</td>
<td>-0.4</td>
<td>3.1*</td>
</tr>
<tr>
<td>White Non-Hispanicc</td>
<td>0.5</td>
<td>0.5</td>
<td>0.4</td>
<td>0.7*</td>
<td>1.6*</td>
</tr>
<tr>
<td>Black</td>
<td>0.5</td>
<td>0.3</td>
<td>0.5</td>
<td>1.0*</td>
<td>1.3</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>0.6</td>
<td>0.5</td>
<td>0.7</td>
<td>2.0</td>
<td>-</td>
</tr>
<tr>
<td>Amer Ind/Alaska Natc</td>
<td>Total U.S.</td>
<td>-</td>
<td>0.3</td>
<td>-0.5</td>
<td>3.0*</td>
</tr>
<tr>
<td></td>
<td>CHSDA Counties</td>
<td>-</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Non-CHSDA Counties</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>-0.5</td>
<td>3.0*</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute.

a Statistic not shown. Rate based on less than 16 cases for the time interval.
b Trend based on less than 10 cases for at least one year within the time interval.
c The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
d The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.
e The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey.
g The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007.
h Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
i Incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

National Cancer Institute
SEER Incidence and US Death Rates
Cancer of the Thyroid, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Table 27.15
Cancer of the Urinary Bladder

SEER Incidence (Invasive and In Situ) and U.S. Mortality
Age-Adjusted Rates and Trends<sup>a</sup>
By Race/Ethnicity and Sex

<table>
<thead>
<tr>
<th>RACE/ETHNICITY</th>
<th>SEER 17 Areas&lt;sup&gt;b&lt;/sup&gt; Rate 2003-2007 Rate per 100,000 persons</th>
<th>SEER 13 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;c&lt;/sup&gt; AAPC (%)</th>
<th>SEER 9 Areas&lt;sup&gt;b&lt;/sup&gt; Trend 1998-2007&lt;sup&gt;d&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Males</td>
<td>Females</td>
<td>AAPC (%)</td>
</tr>
<tr>
<td>All Races</td>
<td>21.1</td>
<td>37.2</td>
<td>9.2</td>
</tr>
<tr>
<td>White</td>
<td>22.8</td>
<td>40.4</td>
<td>9.8</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>11.2</td>
<td>19.5</td>
<td>5.1</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>24.5</td>
<td>43.2</td>
<td>10.5</td>
</tr>
<tr>
<td>Black</td>
<td>12.8</td>
<td>20.7</td>
<td>7.6</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>9.1</td>
<td>16.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>7.7</td>
<td>13.3</td>
<td>3.2</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>11.0</td>
<td>19.2</td>
<td>5.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. Mortality&lt;sup&gt;g&lt;/sup&gt;</th>
<th>Rate 2003-2007 Rate per 100,000 persons</th>
<th>Trend 1998-2007&lt;sup&gt;h&lt;/sup&gt; AAPC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RACE/ETHNICITY</td>
<td>Total Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Races</td>
<td>4.3</td>
<td>7.5</td>
</tr>
<tr>
<td>White</td>
<td>4.5</td>
<td>7.9</td>
</tr>
<tr>
<td>White Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>2.4</td>
<td>4.0</td>
</tr>
<tr>
<td>White Non-Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.6</td>
<td>8.2</td>
</tr>
<tr>
<td>Black</td>
<td>3.7</td>
<td>5.4</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.6</td>
<td>2.6</td>
</tr>
<tr>
<td>Amer Ind/Alaska Nat&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Total U.S.</td>
<td>1.7</td>
</tr>
<tr>
<td>CHSDA Counties</td>
<td>1.8</td>
<td>3.0</td>
</tr>
<tr>
<td>Non-CHSDA Counties</td>
<td>1.6</td>
<td>2.3</td>
</tr>
<tr>
<td>Hispanic&lt;sup&gt;e&lt;/sup&gt;</td>
<td>2.3</td>
<td>3.9</td>
</tr>
</tbody>
</table>

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval. The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 17 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 2 Joinpoints over diagnosis years 1992-2007. The 1998-2007 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1975-2007. Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2003-2007 Hispanic and Non-Hispanic death rates exclude deaths from the District of Columbia, New Hampshire, and North Dakota. The 1998-2007 Hispanic and Non-Hispanic mortality trends exclude deaths from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties. US Mortality Files, National Center for Health Statistics, CDC. The 1998-2007 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2007. The APC is significantly different from zero (p<.05).
SEER Incidence and US Death Rates
Cancer of the Urinary Bladder, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics include cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

Figure 27.2
SEER Incidence and US Death Rates
All Cancer Sites, Ages <20, Both Sexes
Joinpoint Analyses for Whites and Blacks from 1975-2007
and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2007

Incidence

Mortality

Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

Regression lines are calculated using the Joinpoint Regression Program Version 3.4.3, April 2010, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2007 period allow a maximum of 4 joinpoints. Analyses for other ethnic groups during the period 1992-2007 allow a maximum of 2 joinpoints.

API = Asian/Pacific Islander.
AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from Connecticut, the District of Columbia, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Figure 29.2

Childhood Cancer: SEER Incidence Rates 2003-2007 by ICCC Group (includes Group III benign brain (2004-2007) and myelodysplastic syndromes) and Race/Ethnicity Both Sexes, Under 20 Years of Age

Rate per 1,000,000

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>I - Leukemia</th>
<th>II - Lymphoma</th>
<th>III - Brain/CNS</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>50.4</td>
<td>30.0</td>
<td>37.5</td>
<td>54.8</td>
</tr>
<tr>
<td>Black</td>
<td>35.0</td>
<td>29.6</td>
<td>22.3</td>
<td>19.6</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>52.6</td>
<td>28.7</td>
<td>18.2</td>
<td>34.6</td>
</tr>
<tr>
<td>Asian or Pacific Islander</td>
<td>55.9</td>
<td>33.8</td>
<td>9.3</td>
<td>54.8</td>
</tr>
<tr>
<td>Hispanic</td>
<td>52.6</td>
<td>28.7</td>
<td>19.6</td>
<td>54.8</td>
</tr>
</tbody>
</table>

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). Incidence rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) and are not shown for fewer than 10 cases for the time period.


a Rate for Group III (Brain/CNS) includes benign brain tumors and is based only on cases diagnosed in 2004-2007
b Incidence rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.
Childhood Cancer
5-Year Observed Survival (%) by ICCC Group\textsuperscript{a} and Race/Ethnicity
Both Sexes, Under 20 Years of Age, 1999-2006

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2006. The remaining 13 SEER Areas contribute cases for the entire period 1999-2006.


Excludes myelodysplastic syndromes (MDS) and benign brain tumors.

American Indian/Alaska Native. Survival data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Survival data for Hispanics are based on NHIA and excludes cases from the Alaska Native Registry and Kentucky.